Podcasts about Phase

Ray Didinger and Derrick Gunn bring you "Birds Weekly" on Inside The Birds in which they break down the Eagles' 29-18 win over the Commanders on Saturday to clinch the NFC East for the Birds.And also catch the great anecdotes from both veteran reporters!--► Subscribe to our Patreon Channel for exclusive information not seen or heard anywhere else and become among smartest Birds fans out there (just ask our members!!) + get all of our shows commercial free and a lot more!!:https://www.patreon.com/insidethebirds►Support our sponsors!!► Simpli Safe Home Alert System: https://simplisafe.com/BIRDS for 60% OFF!► Camden Apothecary: https://camdenapothecary.com/► Soul Out of Office Gummies: https://getsoul.com. Use Promo Code: BIRDS for 30% off► Sky Motor Cars: https://www.skymotorcars.com/Follow the Hosts!► Follow our Podcast on Twitter: https://twitter.com/InsideBirds► Follow Geoff Mosher on Twitter: https://twitter.com/geoffpmosher► Follow Adam Caplan on Twitter: https://twitter.com/caplannfl► Follow Greg Cosell on Twitter: https://twitter.com/gregcosellNFL insider veterans take an in-depth look that no other show can offer! Be sure to subscribe to stay up to date with the latest news, rumors, and discussions.► Sign up for our newsletter! • Visit http://eepurl.com/hZU4_n.For more, be sure to check out our official website: https://www.insidethebirds.com.

Do you find traditional meditation impossible because your brain won't stop buzzing? Are you terrified of "zoning out" while driving?In this special "Active Alertness" episode of Calming Anxiety, we break the biggest rule of meditation: We keep our eyes open.Designed specifically for the daily commuter, this session transforms your car or train ride from a source of stress into a tool for focus. Instead of trying to empty your mind, we give your brain a job to do—using tactile grounding and visual engagement to hack your nervous system into a state of calm alert.In this 10-minute session, you will learn:The "Safety First" Protocol: How to meditate while keeping your eyes strictly on the road.Tactile Grounding: Using the steering wheel or floor as an anchor to stop anxiety spiraling.The "Color Quest": A neurodivergent-friendly visual game to sharpen focus and replace intrusive thoughts.The "Red Light Reset": How to reframe traffic jams and stops as biological reset buttons for your stress levels.⚠️ SAFETY NOTE: If you are driving, your eyes must remain open and focused on the road at all times. Your safety is the primary meditation.⏱️ Timestamps:00:00 – Intro: Why standard meditation fails commuters01:00 – Safety Disclaimer (Eyes Open!)01:30 – Phase 1: Tactile Grounding (The Anchor)03:00 – Phase 2: Visual Engagement (The Color Game)05:30 – Phase 3: Reframing "The Stops" (Red Lights as Resets)07:50 – The Arrival Protocol: Transitioning to your day09:15 – Final thoughts with MartinConnect with Martin: I'm Martin, a Clinical Hypnotherapist and the creator of Calming Anxiety. My goal is simple: to help you find your best life. I ask for nothing in return but your happiness. Smile often, and be kind to your beautiful self.Do you know a friend or colleague who arrives at work stressed, or battles with morning 'road rage'?Don't let them start another day in chaos. Tap the 'Share' button on this episode and text it to them right now with the message: 'Try this on your drive today.' You might just transform their entire morning—and yours, too."

The Marvel Cinematic Universe officially kicks off Phase 6 with Fantastic Four: First Steps, and Giant Mess podcast host Neal Lynch has a LOT to say about it.In this episode of Giant Mess, I break down Marvel's retro-futuristic, 1960s-set reboot of the Fantastic Four — from the stunning visuals and cosmic scale to the big creative swings (and safe choices) that have fans divided.I dig into:Why this is the best Fantastic Four movie yet — but still feels restrainedThe decision to skip an origin story (and why that mostly works)Galactus as a true cosmic threat (finally done right)Julia Garner's Silver Surfer and whether the character still connects with modern audiencesPedro Pascal, Vanessa Kirby, Joseph Quinn & Ebon Moss-Bachrach's performancesHow Sue Storm is a tour-de-forceCut villains, MCU Easter eggs, and what this movie sets up nextI also dive into Fantastic Four movie history, Marvel rights chaos, and where this reboot fits into the bigger MCU multiverse picture — with plenty of side tangents, sarcasm, and interstellar energy along the way.

**APPLICATIONS CLOSE 12/31/25 FOR IMPACT COLLECTIVE MASTERMIND** What happens when your consulting business no longer needs you in the work but needs you to lead the leaders? In this final episode of the Growing Pains series, I break down what it really takes to build a Scalable Firm. This phase, often experienced somewhere between $1M and $3M in revenue, is defined by adding leadership layers, stepping fully into the CEO role, and creating the operational clarity required to support a growing team. I share why letting leaders lead is essential, how complexity increases as your client base and team expand, and what can happen when scalable operations are skipped. I also close with a final vignette of Jean, our fictional consultant, to illustrate what this stage can look like when it's navigated with intention and strong leadership. This episode is for nonprofit consultants who want to build a firm that creates real impact, supports their life, and actually works. Better Together!

​Attorney General Pam Bondi's recent announcement of releasing additional files related to Jeffrey Epstein has been met with skepticism, particularly following the underwhelming "Phase 1" release. The initial batch, which Bondi had hyped as containing "sick" revelations, primarily consisted of previously available flight logs and heavily redacted documents, offering little new information. This anticlimactic disclosure led to disappointment among the public and conservative influencers, who had anticipated more substantial revelations. Critics argue that the fanfare surrounding the release was disproportionate to its actual content, raising questions about the transparency and intentions behind these actions.In response to the backlash, Bondi has assured the public that more comprehensive documents will be forthcoming, blaming the initial shortcomings on the FBI's alleged withholding of thousands of pages. She has demanded that these documents be delivered to her office promptly, emphasizing a commitment to full transparency. However, given the previous overpromising and underdelivering, many remain skeptical about the authenticity and potential impact of the upcoming releases.to contact me:bobbycapucci@protonmail.comsoruce:Attorney General Pam Bondi insists more Jeffrey Epstein files are being released – despite disastrous ‘phase 1' | The IndependentBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-moscow-murders-and-more--5852883/support.

Send us a textAre you stuck in the question that never seems to get answered: Should I stay or should I go?Some days your relationship feels warm enough to keep trying. Other days it feels so lonely you can't believe you're still sharing the same space. If you're in that place right now, you're not alone, and you're not broken.In this special rebroadcast of one of our most impactful episodes, we dive into what we call the Land of Maybe: the exhausting in-between where couples linger for years, hoping things will change, while quietly running out of emotional gas.Here's the truth most people don't hear soon enough: couples wait an average of six years to get help. By the time they do, it's not just about conflict anymore, it's about exhaustion, disconnection, and not knowing what to do next.In this episode, you'll learn:What the Land of Maybe actually looks and feels like inside a relationshipWhy “some days yes, some days no” is emotionally unsustainableHow blame, avoidance, and waiting it out keep couples stuckWhy relationship struggles are almost always skills problems, not love problemsHow to slow down instead of making fear-based decisionsSimple ways to “switch it up” so you can get new information and clarityHow one person can begin changing the dynamic, even if the other is hesitantIf you're navigating space or separation, this episode is especially important. Space can be a reset, or it can quietly become a slow exit, depending on what you do during it. We'll help you understand the difference and show you how to move through this season with intention instead of panic.Whether you've listened to this episode before or you're brand new to Love Shack Live, we invite you to listen with fresh ears. You're not the same person you were the first time you questioned your relationship, and your relationship isn't the same either.This conversation is about clarity. About skills. And about helping you stop spinning so you can start moving forward in a way that honors you, your partner, and what you truly want next.Need Support?If this episode stirred something in you and you're tired of carrying the “maybe” alone, you don't have to figure out your next step by yourself.Tom offers a free clarity call to help you slow things down, get grounded, and see your situation more clearly, without pressure or pushing you in any direction. Whether you're trying to repair, navigating space, or simply need help deciding what you can't keep carrying, this call is designed to bring calm, perspective, and direction.Couples wait an average of six years to get support. If you're already here, questioning and exhausted, the time is now.You can book your clarity call at stacibartley.com/apply.Clarity comes before big decisions. Support comes before repair.Timestamps: 02:03 Navigating the Land of Maybe06:34 Client Story: Janet and Rich09:07 Understanding and Changing Behavior16:27 The Importance of Practice and Support28:23 Convincing a Resistant Partner28:55 Blame and Guilt in Relationships29:35 The Impact of Physical Attraction31:13 Effective Communication Strategies31:58 Personal Experience and Real-Life Examples34:32 Navigating Conflicted Feelings36:43 The Importance of Slowing Down38:31 Switching Things Up in Relationships40:00 The Catalyst Effect in Relationships45:04 The Power of Humor and Fun51:32 Final Thoughts and Resources

À Rose-Hill : Devenu un danger public, l'Atrium sera bientôt détruit après une première phase de sécurisation ce dimanche by TOPFM MAURITIUS

Justice Department released the first batch of files on the late sex offender and accused trafficker Jeffrey Epstein, but Deputy Attorney General Todd Blanche say not all of the files will be released by today's deadline as required under law; President Donald Trump announces deals with nine pharmaceutical company to lower drug prices; President travels to North Carolina for a speech on affordability and to support Republican Senate candidate Michael Whatley; Federal court hearing in the last surviving case against President Trump over his alleged role in the January 6, 2021 attack on the U.S. Capitol; Secretary of State Marco Rubio holds an end-of-the-year news conference, getting questions on the U.S. policy towards Venezuela, moving to Phase 2 of the Israel-Hamas ceasefire and talks to end the war between Russia and Ukraine. Learn more about your ad choices. Visit megaphone.fm/adchoices

Your daily news in under three minutes. At Al Jazeera Podcasts, we want to hear from you, our listeners. So, please head to https://www.aljazeera.com/survey and tell us your thoughts about this show and other Al Jazeera podcasts. It only takes a few minutes! Connect with us: @AJEPodcasts on X, Instagram, Facebook, and YouTube

​Attorney General Pam Bondi's recent announcement of releasing additional files related to Jeffrey Epstein has been met with skepticism, particularly following the underwhelming "Phase 1" release. The initial batch, which Bondi had hyped as containing "sick" revelations, primarily consisted of previously available flight logs and heavily redacted documents, offering little new information. This anticlimactic disclosure led to disappointment among the public and conservative influencers, who had anticipated more substantial revelations. Critics argue that the fanfare surrounding the release was disproportionate to its actual content, raising questions about the transparency and intentions behind these actions.In response to the backlash, Bondi has assured the public that more comprehensive documents will be forthcoming, blaming the initial shortcomings on the FBI's alleged withholding of thousands of pages. She has demanded that these documents be delivered to her office promptly, emphasizing a commitment to full transparency. However, given the previous overpromising and underdelivering, many remain skeptical about the authenticity and potential impact of the upcoming releases.to contact me:bobbycapucci@protonmail.comsoruce:Attorney General Pam Bondi insists more Jeffrey Epstein files are being released – despite disastrous ‘phase 1' | The Independent

The Maui County Council has passed a measure to phase out short-term vacation rentals; Sierra Lynne Stone, a sixth-generation kalo farmer on the North Shore of Kauaʻi, shares how her family's farm has grown

It's Christmas time and Joe McHale is fully in his murder dad phase. He's playing dad's of questionable morals in all kinds of horror movies. We're doing a queer teen take on It's a Wonderful Life. Oh and also there's a dude dressed as a spooky angel runnin around stabbin people! But that's alright, because our Mr. Potter for this life is played by Justin Long who is doing A VOICE! It's a movie full of choices and we support nearly all of them!Who's our guest?Matthew JacksonBluesky @awalrusdarklyPodcast: Scares that Shaped UsWebsite: MatthewJacksonWrites.comWho's responsible for this?Director: Tyler MacIntyre (Tragedy Girls)Writers: Michael Kennedy (Freaky, Time Cut, Heart Eyes)Stars: Jane Widdop, Joel McHale, Justin Long, Jess McLeod (trans nb), Katharine Isabelle, Aiden Howard, Hana Huggins, William B DaviesWhat should you check out next?Matthew - Silent Night, Deadly Night (2025), Freaky, Heart EyesEmily- X-FilesBen - Freaky, BottomsJeremy - Time Cut, Tragedy GirlsTake our listener survey: http://bit.ly/progressivelyhorrified-surveySign up to support Progressively Horrified on Patreon for as little as $5 a month and get bonus episodes! https://www.patreon.com/c/progressivelyhorrified Hosted on Acast. See acast.com/privacy for more information.

Terry Lynch, CEO of Power Metallic Mines (TSX.V: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV), joins me for a comprehensive exploration update from their fully funded 100,000-meter drill program at the polymetallic NISK Project in Quebec.  We discuss recent drill results from a deep hole at the Lion Zone, pending results still at the assay lab, but also look ahead to 4 key exploration targets of interest for early 2026 drilling.   Key Highlights from the Interview:   Exploration Strategy: A six-rig program focused on expanding the mineralized around the Lion Zone and at depth in the “elephant zone,” and also at Lion West, at the Tiger Deep Zone, and new polymetallic targets from surveys at the Hydro Fold-Hinge Zone. Additionally the team is still drilling to connect the 5.5km corridor and “Gap Area” between Lion and NISK Main.  There are still about 15,000-20,000 meters of core being processed at the lab that should be back by late January, and then 65,000 additional meters that will be drilled throughout 2026. 40 Meters of 12.18% Cu (14.34% CuEqRec) included within 20.40 meters of 2.91% Cu (3.58% CuEqRec) in Hole 25-029b at Lion, and Completes the Extension of PN-24-064 “elephant hole” to define large BoreHole EM anomaly at depth.    Terry points out that the exploration team is more animated by the follow up hole here after collecting more electro-magnet information from this most recent hole. Resource Growth Path: Early-stage modeling efforts are enabling analysts and investors to build their own interpretations of scale, while metallurgical studies are underway with results set to release in early Q1 to confirm high recovery rates. Acquisition of Li-FT Power land:  Back on July 14, 2025 the Company announced that it closed a definitive agreement dated June 9, 2025 to acquire a 100% interest in 313 mineral claims totalling 167 km² from Li-FT Power Ltd. (TSXV: LIFT) (OTCQX: LIFFF). The claims adjoin the Company's 45.86km² Nisk property, where exploration is expanding the high–grade Lion Cu–PGE discovery and the Nisk Copper-Nickel-Platinum-Palladium-Gold-Cobalt deposit.   Terry explains how there are 8 very high priority drill targets that the exploration team is following up on across this newly acquired land. Phase 1 Metallurgical Testing of Lion Deposit:  On Oct. 16th, Power Metallic announced that preliminary metallurgical studies are underway being performed by SGS Canada Ltd at its laboratories based in Quebec City, QC, and Lakefield, ON. Work to date has shown that the copper mineralization is contained within coarse grained chalcopyrite and cubanite, both which should respond well to conventional sulphide concentration methods. Overall, the character of the mineralization suggests good recoveries of copper sulphides, and these initial metallurgical tests will determine the recovery potential of the PGEs, Au, Ag, and Ni., which are expected to report within a conventional sulphide concentrate.   If you have any questions for Terry regarding Power Metallic Mines, then please email them into me at Shad@kereport.com.   * In full disclosure, Shad is a shareholder of Power Metallic Mines at the time of this recording, and may choose to buy or sell shares at any time.   Click here to follow the latest news from Power Metallic Mines   For more market commentary & interview summaries, subscribe to our Substacks:   The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/     Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.

Buy/Stream: https://overview.fanlink.tv/OVR120-Epitome-II Overview Music's flagship VA series 'Epitome' returns for it's second installment with an stellar cast of contemporary, forward-thinking artists from the Drum & Bass landscape of 2025. Phase Instagram → https://www.instagram.com/phasednb Facebook → https://www.facebook.com/phasednb Soundcloud → https://soundcloud.com/phasednb Overview Music Patreon → https://patreon.com/overview Facebook → https://facebook.com/overviewuk Instagram → https://instagram.com/overviewuk Soundcloud → https://soundcloud.com/overviewuk YouTube → https://youtube.com/@OverviewMusic

Tim Shearcroft,  CEO and Co-Founder of BP Silver Corp. (TSXV: BPAG), joins me for a comprehensive introduction to this newly listed silver and polymetallic exploration company focused on exploration of their flagship asset, the Cosuño Project; which is strategically located in the prolific Bolivian silver belt. Additionally, the Company is working on finalizing the title at their Titiri Project, located in a major under-explored silver belt with Tier 1 discovery potential.   We start off getting an overview of how the Company, projects, and team came together privately and then it was just publicly listed on September 29th of this year.  We discuss the prospectivity of Bolivia for mineral exploration and exploitation, the handful of companies that have made solid advancements on their projects in country, and how the political administration has recently changed to become more amenable to foreign business investment and mineral extraction.    Next we get into the details announced on December 17th, highlighting the successful completion of its Phase 1 diamond drilling program at the Cosuño Silver Project, located in the Department of Potosí, Bolivia. A total of 11 diamond drill holes totaling 906 meters were completed, testing four high-priority targets in the lithocap that may host an epithermal silver deposit. Samples from the first two drill holes have been submitted to an independent geochemical laboratory for analysis. Final core logging, sample preparation, and shipment of the remaining samples will be completed prior to the conclusion of the program later in December, with initial assay results expected in early January 2026.   Additionally, their team is working with the government to finalize obtaining the title to begin exploration on their Titiri Project.   Titiri was staked over a large land concession containing outcropping mineralization historically explored by ASARCO.  This Project contains a 2.5km-long silver-lead-zinc zone, with excellent historical trench results, that was never drilled. Titiri is a very High Priority structural setting at the intersection of several major crustal-scale faults, along which multiple deposits occur.  There is a MOU in place with local communities, and they'd like to get on the ground for exploration in mid-2026.   Wrapping up, Tim shared his background and the experience of their strong technical team and with a substantial experience exploring and operating in Bolivia and Latin America. We covered the financial health of the company, share structure and warrants, and envisioned work strategy and plan moving into next year.   If you have any questions for Tim regarding BP Silver, then please email those into me at Shad@kereport.com.   Click here to follow the latest news for BP Silver   For more market commentary & interview summaries, subscribe to our Substacks:   The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/     Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.  

Heute widmen wir uns der Entwicklung und Bedeutung der deutschen Kriegsmarine in der Zeit zwischen den beiden Weltkriegen sowie während des Zweiten Weltkriegs. Im Zentrum unserer Betrachtung stehen zwei prägende Persönlichkeiten der Marinegeschichte: Erich Raeder, der von 1928 bis 1943 als Oberbefehlshaber die Geschicke der Kriegsmarine leitete, und sein Nachfolger Karl Dönitz, der später für kurze Zeit auch das Amt des Staatsoberhauptes des Deutschen Reiches übernahm. Zunächst beschäftigen wir uns mit Raeders Bemühungen, die Marine nach den Beschränkungen des Versailler Vertrags wiederaufzubauen. Dabei spielen sowohl die organisatorischen und politischen Herausforderungen dieser Phase eine Rolle als auch die strategischen Leitlinien, die Raeder für die zukünftige Ausrichtung der Seestreitkräfte entwickelte. Ein besonderer Schwerpunkt liegt auf dem sogenannten Z-Plan, jenem ambitionierten Rüstungsprogramm, das den Aufbau einer schlagkräftigen Überwasserflotte vorsah und langfristig die globale Bedeutung Deutschlands zur See stärken sollte. Im Anschluss wenden wir uns Karl Dönitz zu, dessen Aufstieg in der Marine eng mit der Entwicklung der deutschen U-Boot-Waffe verknüpft ist. Wir beleuchten seine strategischen Vorstellungen, insbesondere die Theorie des „Rudeltaktik“-geführten U-Boot-Krieges, sowie die technischen Neuerungen und taktischen Anpassungen, die unter seiner Führung umgesetzt wurden. Diese Faktoren prägten maßgeblich den Verlauf des Seekrieges im Atlantik und beeinflussten sowohl die Erfolge als auch die Grenzen der deutschen U-Boot-Operationen während des Zweiten Weltkriegs.

In this podcast episode, Dr. Jonathan H. Westover talks with Lamell J. McMorris about his book, THE POWER TO PERSIST: 8 Simple Habits To Build Lifelong Resilience. Lamell J. McMorris is a nationally recognized entrepreneur, activist, and changemaker dedicated to advancing equity and revitalizing underserved communities. Growing up on the South Side of Chicago, he went on to find phenomenal success as a D.C. policymaker, a consultant in the financial and professional sports arenas, and a civil and human rights advocate. McMorris is the founder and CEO of the Washington, D.C.-based company Phase 2 Consulting, which offers strategic insight and external affairs services to some of the nation's leading decision-makers in the private, public, and nonprofit sectors, including Fortune 100 companies. He is also founder and managing principal of Greenlining Realty USA, a comprehensive urban redevelopment firm dedicated to neighborhood investment, redevelopment, housing rehabilitation, and home improvement in low-income communities. He holds a BA in Religion and Society from Morehouse College, a MDiv in Social Ethics and Public Policy from Princeton Theological Seminary, and a DLP in Law and Policy from Northeastern University. Check out all of the podcasts in the HCI Podcast Network!

Jan Winhall is a psychotherapist, author, educator, and the developer of the Felt Sense Polyvagal Model (FSPM), a groundbreaking framework that integrates trauma therapy, polyvagal theory, and embodied focusing to understand and treat addiction and trauma. Over more than four decades of clinical work, Jan has specialized in supporting survivors of sexual violence, complex trauma, and addiction with a deeply de-pathologizing, feminist, and body-based lens. She is the founder of the Felt Sense Polyvagal Model Institute, teaches internationally, and collaborates closely with leaders in the polyvagal community to bring more compassionate, somatically grounded approaches into trauma and addiction treatment. In this powerful and deeply validating conversation, Clarissa and Molly sit down with trauma and addiction therapist Jan Winhall, creator of the Felt Sense Polyvagal Model (FSPM). Jan weaves together feminist therapy, trauma theory, polyvagal theory, and embodied practice to completely reframe how we understand addictive behaviors like binging, purging, and compulsive eating: not as "problems" or "defects," but as adaptive state-regulation strategies that the body uses to survive overwhelming experiences. Jan shares how early work with incest survivors revealed the harms of pathologizing, top-down psychiatric approaches—and how safety, dignity, and deep listening became the foundation for her model. Together, we explore how nervous-system states, shame, trauma, ADHD, and body image intersect with ultra-processed food addiction, and how recovery becomes possible when we work with the body instead of against it. This episode is for clinicians, helpers, and anyone living with food addiction who has ever wondered: "What if nothing about me is broken—and my body has been trying to keep me alive all along?" In This Episode, We Explore: • Jan's Origins in Trauma Work o Running groups for young women who were incest survivors in a small Ontario hospital o Seeing firsthand the limitations and harm of traditional psychiatric models o How feminist therapy and the work of Judith Herman and Sandra Butler helped de-pathologize survivors   • From "What's Wrong With You?" to "What Happened to You?" o Why behaviors often labeled "manipulative" or "attention-seeking" (e.g., binging, purging, self-harm) are actually survival strategies o Understanding these behaviors as ways to regulate overwhelming nervous-system states, not moral failures   • The Felt Sense & Polyvagal Theory – Explained Accessibly o What "felt sense" really means (beyond just "sensation") o How neuroception constantly scans for safety and danger below conscious awareness o The three main autonomic states:  Ventral vagal – safety, connection, social engagement  Sympathetic – fight/flight, agitation, urgency  Dorsal vagal – shutdown, collapse, numbness, shame o How addictive behaviors help the body shift between these states to survive   • Addiction as a Trauma Feedback Loop o Why the body cannot stay in high sympathetic arousal or deep shutdown forever o How food, substances, sex, and other behaviors become "jolts" that move us between states o The idea of a "trauma feedback loop" where trauma, dysregulation, and addiction constantly reinforce each other   • Working with Trauma Without "Fishing" for It o Why Jan no longer goes "hunting" for trauma stories o The importance of Phase 1 work: establishing safety before uncovering trauma o How to help people gently reconnect with the body (starting at the edges: fingertips, earlobes, etc.) before approaching the more overwhelming inner experiences   • Shame, Addiction, and Liberation o Why shame is so central to trauma and addiction—and why Jan actually loves working with it o Reframing shame: "This is what bodies do under threat; you are not uniquely broken." o How truly believing this (in our own bodies) changes how we show up for clients o Using groups, co-regulation, and shared stories to create "moments of liberation"   • Food & Sex Addiction, Early Trauma, and Access o Why food and sex are often the earliest available forms of self-soothing for children in unsafe environments o How early masturbation and secret eating can evolve into entrenched patterns over decades o The stigma that keeps men with food addiction silent and unseen   • ADHD, Neurodivergence & Addiction o How neurodivergent folks are especially vulnerable to regulation difficulties and shame o The clash between ADHD time perception and linear, "on-time" culture o The dopamine-driven ping-pong between shame (dorsal) and activation (sympathetic), and how this sets up classic addictive pathways o The "neuroplastic paradox" – getting stuck in ruts, and how intentional practice can build new pathways   • Body Image, Misogyny & Reclaiming the Body o Why so many clients experience their body as "the enemy" o How misogyny, hyper-masculinity, and purity culture shape body hatred and silence around food addiction o The role of our own relationship with our bodies as therapists and helpers—how we co-regulate clients through our presence, not just our words   • Receiving Love & Positive Feedback as a Trigger o Why compliments, affection, and warmth can feel more threatening than criticism for many addicted bodies o How to normalize this, slow it down, and help the nervous system "update" that it is safe enough now o Using group moments of discomfort as live material to work with neuroception and triggers   • Self-Disclosure, Accessibility & Doing Our Own Work o Why Jan believes safe, boundaried self-disclosure can create powerful safety o Steve Porges' idea that "the greatest gift you can give is your accessibility" o Why clinicians must apply these models to their own lives first, so that their belief in the body's wisdom is genuine   • Changing the Addiction Treatment Paradigm o The trauma of addiction treatment itself—shaming, punitive, expensive models o Jan's commitment to bringing compassionate, somatic, polyvagal-informed approaches into 12-step spaces and beyond o The importance of connecting communities (like Sweet Sobriety and FSPM) to shift the field together   Follow Jan and the FSPM Institute: https://www.fspminstitute.com The content of our show is educational only. It does not supplement or supersede your healthcare provider's professional relationship and direction. Always seek the advice of your physician or other qualified mental health providers with any questions you may have regarding a medical condition, substance use disorder, or mental health concern.  

As a mysterious hooded traveler sits us down to explain the origins of Thra, we find ourselves joined by Jake Beal, who helps us usher in Phase 8 of the podcast! We catch up on Star Visions season 3 and some recent Star Wars comics and chat about our personal histories with The Dark Crystal, before diving into our new adventure and the strange, wonderful, and terrible world of Gelflings, Skeksis, Aughra, Raunip, and Gyr! 

Send us a textWelcome back Rounds Table Listeners! In our year-end episode, Drs. Mike and John Fralick discuss five important research studies published in 2025:Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO) (0:00 – 4:20)Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT) (4:21 – 9:30)Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation (AQUATIC) (9:31 – 15:03)Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial (FRESH-UP) (15:04 – 18:09)Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (ESSENCE) (18:10 – 23:49)The Good Stuff (23:50 – 25:27):Toronto Star Santa Claus Fund, Calgary Food Bank, The War Amps Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

The company has also fully enrolled the Phase 2/3 VISTA clinical trial for its XLRP gene therapy.

Send us a textIn this episode of WTR Small-Cap Spotlight, host Tim Gerdeman and analyst Robert Sassoon speak with Shaun Bagai, CEO of RenovoRx (NASDAQ: RNXT). The company is pioneering targeted oncology therapies and commercializing RenovoCath™, an FDA-cleared multi-specialty local drug delivery device for high unmet needs. We discuss the innovation and advantages of its TAMP™ (Trans-Arterial Micro-Perfusion) platform—powered by the proprietary dual-balloon catheter—and how it sets RenovoRx apart in treating hard-to-reach hypovascular tumors like pancreatic cancer. The conversation also covers RenovoCath's commercialization strategy and key milestones in its Phase 3 clinical trial aimed at proving the platform's delivery superiority over the current standard of care.

Drs Joseph Mikhael and Shaji Kumar discuss the future of multiple myeloma, including enhanced diagnostics for detecting myeloma, frontline therapy, and durable responses. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002718. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Multiple Myeloma https://emedicine.medscape.com/article/204369-overview Updated Diagnostic Criteria and Staging System for Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/27249749/ Mass Spectrometry for the Evaluation of Monoclonal Proteins in Multiple Myeloma and Related Disorders: An International Myeloma Working Group Mass Spectrometry Committee Report https://pubmed.ncbi.nlm.nih.gov/33563895/ Multiple Myeloma Imaging https://emedicine.medscape.com/article/391742-overview Next-Generation Biomarkers in Multiple Myeloma: Understanding the Molecular Basis for Potential Use in Diagnosis and Prognosis https://pubmed.ncbi.nlm.nih.gov/34299097/ Monoclonal Gammopathy of Undetermined Significance https://www.ncbi.nlm.nih.gov/books/NBK507880/ Primary Plasma Cell Leukemia: Consensus Definition by the International Myeloma Working Group According to Peripheral Blood Plasma Cell Percentage https://pubmed.ncbi.nlm.nih.gov/34857730/ Advancing MRD Detection in Multiple Myeloma: Technologies, Applications, and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/40214184/ Genomic Landscape of Multiple Myeloma and Its Precursor Conditions https://pubmed.ncbi.nlm.nih.gov/40399554/  Quadruplet Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis https://pubmed.ncbi.nlm.nih.gov/39348665/ Subcutaneous Daratumumab (Dara) + Bortezomib/Lenalidomide/Dexamethasone (VRd) With Dara + Lenalidomide (DR) Maintenance in Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Sustained Minimal Residual Disease Negativity in the Phase 3 PERSEUS Trial https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.7501 Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial https://pubmed.ncbi.nlm.nih.gov/39841461/ Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant Is Not a Medically Suitable Treatment https://www.clinicaltrials.gov/study/NCT05561387 Cytokine Release Syndrome and Associated Neurotoxicity in Cancer Immunotherapy https://pubmed.ncbi.nlm.nih.gov/34002066/ The Role of CELMoD Agents in Multiple Myeloma https://pmc.ncbi.nlm.nih.gov/articles/PMC12399888/ Phase 2 Study of Talquetamab + Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma and Extramedullary Disease: REDIRECTT-1 https://library.ehaweb.org/eha/2025/eha2025-congress/4173809/shaji.kumar.phase.2.study.of.talquetamab.2B.teclistamab.in.patients.with.html Discovery of a Novel Class NSD2 Inhibitor for Multiple Myeloma With t(4;14) https://pubmed.ncbi.nlm.nih.gov/40949769/ Long-Term (≥5 Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel (Cilta-Cel) in CARTITUDE-1 Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.7507

Spoiler warning up top: Frank reacts to the Avengers: Doomsday teaser that's currently playing in theaters and the big headline that comes with it, Chris Evans returning as Steve Rogers. The hype is real, but the conversation gets complicated fast, especially when you zoom out and ask what this says about Marvel's confidence in the post Endgame era. Frank also unpacks the idea (and the risk) of Doomsday being framed as a direct sequel to Endgame, and what a “soft reboot” after Secret Wars could mean for the MCU's future.00:00:00 Spoiler warning and initial reaction to the Avengers: Doomsday teaser and Chris Evans returning00:00:16 The excitement vs. the bigger worry: what this says about Marvel after Endgame00:00:32 Russo Brothers calling Doomsday a direct Endgame sequel and what gets left behind00:00:46 “Soft reboot” talk after Secret Wars and how Marvel rebuilds trust going forward00:01:14 Does this undercut Sam Wilson and the newer era of the MCU?00:01:56 Listener comments requested for the next episodeChris Evans returning as Steve Rogers hits hard emotionally for a lot of fans.The bigger concern is what this signals about Marvel's confidence in newer characters and newer phases.Positioning Doomsday as a direct sequel to Endgame raises questions about how much of Phase 4 and 5 will matter.The “soft reboot after Secret Wars” idea makes comic sense, but it also feels like Marvel resetting the board to safer territory.There's a real tension between hardcore fan concerns and what mainstream audiences will likely love without overthinking it.If Steve comes back, it opens a big conversation about legacy, leadership, and whether Sam Wilson gets pushed aside.“Hell yeah, Chris Evans is back as Steve Rogers.”“This means that basically Marvel doesn't trust anything they put out after Endgame.”“It's not like Steve Rogers doesn't always come back in the comic books.”If you've got thoughts on Chris Evans returning, the Doomsday teaser, and whether this helps or hurts the MCU long-term, send them in. Subscribe to Geek Freaks Headlines, leave a rating and review, and share this episode with #GeekFreaksHeadlines. Frank will pull listener reactions into the next show.GeekFreaksPodcast.comInstagram: https://www.instagram.com/geekfreakspodcast/Twitter: https://twitter.com/geekfreakspodThreads: https://www.threads.net/@geekfreakspodcastFacebook: https://www.facebook.com/thegeekfreakspodcastPatreon: https://www.patreon.com/GeekFreakspodcastWhat's your read on this move: smart crowd-pleaser, panic button, or both? Send your take and we'll feature listener comments in the next episode.Apple Podcast Tags: Marvel, MCU, Avengers Doomsday, Chris Evans, Steve Rogers, Captain America, Russo Brothers, Endgame, Secret Wars, Marvel Studios, Superhero Movies, Pop Culture NewsTimestamps and TopicsKey TakeawaysMemorable QuotesCall to ActionLinks and ResourcesFollow UsListener Questions

„Rosa war in erster Linie nicht nur Regisseur – er war ein schwuler Mann.“ Mit diesen Worten beginnt das Gespräch zwischen Thilo und Martin Kruppe, dem geschätzten Herstellungsleiter unserer Produktionsfirma. Denn Martin hat nicht immer für uns gearbeitet – sondern auch 22 Jahre lang für Rosa von Praunheim. Der Filmregisseur, Produzent, Autor und Aktivist ist gestern, am 17. Dezember verstorben – Anlass für einen sehr persönlichen Rückblick auf sein Werk, seine Haltung und seinen Einfluss auf die LGBTQ-Bewegung in Deutschland und die Frage: Was bleibt? Rosa von Praunheim war weit mehr als ein Filmemacher. Auch wenn er nicht ausschließlich schwule Themen bedient hat, war sein gesellschaftliches Engagement unübersehbar: als Mitbegründer der Berliner Aids-Hilfe, als Wegbereiter queerer Sichtbarkeit im deutschen Fernsehen und als jemand, der sich nie davor gescheut hat, Haltung zu zeigen. Kann man schwul sein, ohne darüber zu reden, dass man schwul ist? Das Gespräch erzählt aber nicht nur von politischem Impact, sondern auch von persönlichen Wegen. Auch Martins eigener Weg zum Film begann durch Rosa. Wie war es damals, als schwuler Mann in der Medienbranche zu arbeiten? Wie kam Martin zu Rosa von Praunheim – und was hat Rosa ihm mitgegeben, das ihn bis heute beim Film hält? Über 150 Filme, dazu unzählige Kurzfilme: War Rosa ein Workaholic? Wie war er als Mensch, abseits der Kamera? War er eine Diva? Für Martin ist eines klar: In jeder Phase des Arbeitens war Rosa spürbar: „Rosa lag etwas am Herzen. Das musste raus. Und dann haben wir einen Film gemacht.“ Rosa hat Rosa gelebt – und alles, was man mit ihm verbindet, war echt. Hast du Fragen, Feedback oder Anmerkungen? Schreib uns eine Nachricht an [amr@pqpp2.de](mailto:amr@pqpp2.de) oder auf Instagram: https://www.instagram.com/allesmussraus_podcast/ und wenn du möchtest unterstütze unsere Arbeit auf Patreon: https://www.patreon.com/c/AllesMussRaus?l=de Du möchtest in „Alles Muss Raus“ werben? Dann hier* entlang: https://podstars.de/kontakt/?utm_source=podcast&utm_campaign=shownotes_alles-muss-raus

Jahresende, Weihnachts-Special, Rückblick & Ausblick – und mittendrin ein Mann, bei dem selbst zwischen den Jahren der Kopf nie stillsteht. In dieser Episode ist Rouven Schröder zu Gast, der neue „Head of Sports“ von Borussia Mönchengladbach. Gleich zu Beginn meldet sich Gladbach-Fan Tommi Schmitt mit einer Sprachnachricht – und trifft damit einen Nerv. Es geht um Schröders Privatleben, um Abschalten, um Weihnachten – und um genau die Frage, die dieser Episode ihren Titel gibt: Warum der Kopf bei Rouven Schröder eigentlich nie aus ist. Schröder erzählt, wie ein Weihnachten ohne Geschenke am Protest seiner Kinder scheiterte, warum Familie für ihn Rückzugsort und Antrieb zugleich ist und weshalb er trotzdem selten wirklich abschalten kann. Kurz darauf wird die Aufnahme unterbrochen: Friedhelm Funkel ruft an. Thema jetzt: Autogrammwünsche und die Frage, warum Funkel eigentlich nie Trainer bei der Borussia war. Schröder erzählt, dass er noch immer im Hotel direkt am Fohlenplatz wohnt und sich das wohl so schnell auch nicht ändern wird. Er gibt Ausblick auf das Trainingslager in der Winterpause, auf bevorstehende Transfers und mögliche Herausforderungen auf der Torhüter-Position. Besonders persönlich wird es, als Rouven Schröder über die Beziehung zu seinem Vater spricht – über Ehrgeiz, über eine schmerzhafte Phase und darüber, warum er sich geschworen hat, seinen eigenen Kindern immer ihr eigenes Ding zu lassen. Ein weiteres Thema: seine absolute Überzeugung in Eugen Polanski. Schröder erklärt, warum Polanski für ihn nie „nur“ ein Interims-Trainer war und wie die Vertragsverhandlungen mit Volker Struth und Sascha Breese den Weg zur Verlängerung erleichtert haben. Und dann wird es natürlich auch noch weihnachtlich: Schröder bekommt selbst ein Päckchen. Sebastian Hellmann hat ein Handy mitgebracht. Warum ihn dieses Geschenk wirklich freut – und weshalb es ausgerechnet ein Klapphandy sein muss – hört ihr in dieser letzten Episode für 2025. „SPIELMACHER - Fußball von allen Seiten“ ist eine Gemeinschafts-Produktion von 360Media und der Podcastbande. Neue Folgen alle 14 Tage donnerstags, überall, wo es Podcasts gibt. Wer es auch sehen will: Als Video-Podcast erscheint „SPIELMACHER - Fußball von allen Seiten" in gekürzter Form bei Sky Sport News und auf YouTube.

SpaceX IPO coming – huge increase in valuation over past 3 months Happy Hanukah – Eight Crazy Nights Now Kevin AND Kevin PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Warm-Up - Last Chance for CTP Cup 2025 participants - Happy Hanukah - Eight Crazy Nights - Sad News - Rob Reiner - Fed decision is out.... - Overdue eco reports coming this week Markets - Oracle still problematic - SpaceX IPO coming - huge increase in valuation over past 3 months - Another Bankruptcy - cleaning up is not good business - Oh my - Now Kevin AND Kevin - Weight loss game continues - One thing saved for last - a doozie... Tesla -  - All time High - Prospect of Robotaxi - Even though sales hitting multi-year lows Wall Street Never Sleeps? - Nasdaq files to extend trading to 23 hours on weekdays - Banks concerned about investor protections, costs, liquidity, volatility risks of nonstop trading - Proponents argue round-the-clock trading benefits global investors - That may create some additional volatility potential SpaceX - SpaceX aims for a potential $1.5 trillion market cap with an Initial Public Offering in 2026, which could become the largest IPO in history - July 2025 tender valuation was $400B - Dec 14th (4 months later) $800B - Starlink is the primary money winner of this deal - Tesla shares climbing even with nothing behind it - seemingly in sympathy for this IPO ---- TESLA does not have ownership of SpaceX - OH - this could be the reason....U.S. deliveries dropped significantly in November—the lowest since early 2022—but this weakness has been overshadowed by the enthusiasm for autonomy. Rob Reiner - A son of legendary Hollywood director Rob Reiner and his wife, producer Michele Singer Reiner, Nick Reiner, is being held on suspicion of murder following their deaths, according to Los Angeles Police Department Chief Jim McDonnell. He's being held on $4 million bail. - Citing law enforcement sources and family friends, ABC News reported on Monday that Nick Reiner had recently returned to live at his parents' South Chadbourne Avenue home. The move was described as a temporary arrangement intended to help him stabilize. - Not going to discuss the Truth Social post about this tragedy HEADLINE ALERT - "Copper could hit ‘stratospheric new highs' as hoarding of the metal in U.S. continues" - Copper has gone from 5.77 to 5.30 (July to today) - 6 Tops at this price since 2011 - Not seeing this as per the headline - seems like a Hunt Brothers special from the 1980s - CORNERING THE MARKET ---1980 - Silver went from $11 to $50 then crashed, bankrupting the Hunt Bros - after COMEX changed rules forcing them to cover positions Bankruptcy - After 35 years, the maker of the Roomba robot vacuum filed for bankruptcy protection late Sunday night. Following warnings issued earlier this year that it was fast running out of options, iRobot says it is entering Chapter 11 protection and will be acquired by its contract manufacturer, China-based Picea Robotics. - The company says it will continue to operate “with no anticipated disruption to its app functionality, customer programs, global partners, supply chain relationships, or ongoing product support.” - Remember that Amazon  - The Amazon buyout of iRobot, maker of Roomba, was announced in 2022 for $1.7 billion but ultimately failed in January 2024 due to significant regulatory pushback, primarily from the EU, over anti-competitive concerns. -- Amazon walked away with a $94 million termination fee Fed Pick - President Donald Trump said Friday that Kevin Warsh has moved to the top of his list as the next Federal Reserve chair, though Kevin Hassett also remains in contention, according to the Wall Street Journal. - Interesting that this comes days after Hassett said that we would not let outside suggestions influence his voting - ---In addition to putting heavier weight on Warsh getting the job, Trump repeated an assertion he has made in the past that the Fed chair ought to consult the president about interest rate decisions. - Also of interest, prediction markets had Hassett at 95% probability - now it moved to 50% - big payday for people in the know. Housing Prices - Average home price is DOWN on  year-over-year basis - First time on national level since 2024 - Active listings in November were nearly 13% higher than November 2024, but new listings were just 1.7% higher --- Houses are on market longer - - Prices in Austin, Texas, are down 10% from last year; in Denver, they're down 5%, according to Parcl Labs. Tampa, Florida, and Houston both saw prices fall 4%, and Atlanta and Phoenix saw price decreases of 3%. More Hosing Related -  Zillow shares plunged more than 9% on Monday on worries that the online real estate platform could have a big new competitor: Google Search. - Google appears to be running tests on putting real estate sale listings into its search results. Overdue Eco  - Black Hole - The U.S. Bureau of Labor Statistics on Tuesday releases its long-awaited combined employment reports for October and November, but a number of key details will be missing after the government shutdown prevented data collection, including October's unemployment rate, resulting in the first-ever gap in that critical data series since inception in 1948. - NICE JOB GANG! - Some of the data will be estimated. - It said it would not publish the headline CPI number or the so-called core CPI, which strips out the volatile food and energy components, for October. "BLS cannot provide specific guidance to data users for navigating the missing October observations," the agency said. Some Updates - Some info coming in are estimates - some delayed - Unemployment at 4.6% - Latest report shows +64,000 added - ISM Manufacturing and Non-manufacturing - both slowed over the last month The Fed - Meanwhile the Fed cuts rates.... - A Federal Reserve split over where its priorities should lie cut its key interest rate Wednesday in a 9-3 vote, but signaled a tougher road ahead for further reductions. - The FOMC's “dot plot” indicated just one more reduction in 2026 and another in 2027, amid considerable disagreement from members about where rates should head. - In addition to the rate decision, the Fed also announced it will resume buying Treasury securities. The central bank will start by buying $40 billion in Treasury bills, beginning Friday. - Markets were all over the place on this as it was a little confusing at first - then it seemed that everyone loved (for one day) - Why is the Fed moving up Treasury purchases to "immediately" from a few months from now? - AND - dissension ! A larger group  that usual of regional Fed bank presidents signaled they opposed the cut, and six policymakers said the benchmark federal funds rate should end 2025 in a range of 3.75% to 4%, suggesting they opposed the move. - Long bonds have not moved at all on this news. Costco Earnings - Costco beat Wall Street's fiscal first-quarter sales and revenue expectations. - Sales rose 8.2% and digital sales jumped 20.5% compared with the year-ago quarter. - Costco surpassed Wall Street's quarterly expectations and posted year-over-year sales growth of 8.2% as the retailer attracted more digital sales and opened new locations. - Earnings per share: $4.50 vs. $4.27 expected - Revenue: $67.31 billion vs. $67.14 billion expected - Costco does not provide year ahead guidance - Shares down from a recent high of $855 Costco Fun Facts - About 4.5 million pies were sold in the three days before Thanksgiving, which is equivalent to roughly 7,000 pies per warehouse. -  These were bakery pies (e.g., pumpkin, apple), - Costco had more than $250 million in non-food online orders on Black Friday, a record for Costco's U.S. e-commerce business. - Approximately 358,000 whole pizzas were served at Costco's U.S. food courts, a 31% jump from last year. (500 pizza's per store) Fat No More - Retatrutide - Eli Lilly said its next-generation obesity drug delivered what appears to be the highest weight loss seen so far in a late-stage trial and reduced knee arthritis pain, clearing the first of several upcoming studies on the weekly injection. - In a 48-week Phase 2 study, participants on the highest dose lost an average of 24% of their body weight. - Recent Phase 3 results showed patients on the highest dose lost an average of 28.7% of their body weight after 68 weeks. - The trials also showed improvements in related health conditions, including knee osteoarthritis pain, blood pressure, and liver fat - This triple action is what makes retatrutide potentially more effective for weight loss than existing medications like Zepbound (tirzepatide), which targets two receptors, or Wegovy (semaglutide), which targets only one. Paypal - PayPal Holdings Inc. applied to become a bank in the US, looking to take advantage of the Trump administration's openness to financial-technology companies entering the banking system. - The payments-focused firm submitted applications to the Federal Deposit Insurance Corp. and the Utah Department of Financial Institutions to form a Utah-chartered industrial loan company, PayPal said in a statement Monday. - If approved, PayPal Bank would help the firm bolster its small-business lending capabilities, according to the statement, which said the company has provided access to more than $30 billion in loans and capital since 2013. Ford - Management Confused - Instead of planning to make enough electric vehicles to account for 40 percent of global sales by 2030—as it pledged just four years ago—Ford says it will focus on a broader range of hybrids, extended-range electrics, and battery-electric models, which executives now say will account for 50 percent of sales by the end of the decade. - The automaker will make hybrid versions of almost every vehicle in its lineup, the company says. - All in on EVS cost them -  Ford expects to record about $19.5 billion in special items, mostly during the fourth quarter. ---- The charges are related to a restructuring of its business priorities and a pullback in its all-electric vehicle investments. Australia - Australia has implemented a groundbreaking ban preventing children under 16 from accessing major social media platforms like TikTok, Instagram, and Facebook, effective December 2025, to protect them from harm, with significant fines for companies failing to enforce it, though messaging apps and gaming platforms are currently exempt. - Reddit is suing - Facebook, Instagram, Snapchat, Threads, TikTok, X (Twitter), YouTube, Reddit, Kick, and Twitch are all banned for kids under 16. - Thoughts on this? Saved For Last - Of all the eye-popping numbers that Oracle Corp. published last week on the costs of its artificial-intelligence data center buildout, the most striking didn't appear until the day after its earnings press release and analyst call. - The more comprehensive 10-Q earnings report that appeared on Thursday detailed $248 billion of lease-payment commitments, “substantially all” related to data centers and cloud capacity arrangements, the business-software firm said. These are due to commence between now and its 2028 financial year but they're not yet included on its balance sheet. - That's almost $150 billion more than was disclosed in the footnotes of September's earnings update. Love the Show? Then how about a Donation? The Winner for iShares Bitcoin Trust ETF (IBIT) Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt! CTP CUP 2025 Participants: Jim Beaver Mike Kazmierczak Joe Metzger Ken Degel David Martin Dean Wormell Neil Larion Mary Lou Schwarzer Eric Harvey (2024 Winner) FED AND CRYPTO LIMERICKS See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Collective Mining has expanded the Ramp Zone. We are seeing new drill results from NGEx and the Phase 4 program at Lunahuasi. New Break Resources have new drill results to report. Drilling at 1911 Gold's Ogama-Rockland deposit has commenced. District Metals applied for more mineral licenses in Sweden. This episode of Mining Stock Daily is brought to you by... Revival Gold is one of the largest pure gold mine developer operating in the United States. The Company is advancing the Mercur Gold Project in Utah and mine permitting preparations and ongoing exploration at the Beartrack-Arnett Gold Project located in Idaho. Revival Gold is listed on the TSX Venture Exchange under the ticker symbol “RVG” and trades on the OTCQX Market under the ticker symbol “RVLGF”. Learn more about the company at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠revival-dash-gold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Vizsla Silver is focused on becoming one of the world's largest single-asset silver producers through the exploration and development of the 100% owned Panuco-Copala silver-gold district in Sinaloa, Mexico. The company consolidated this historic district in 2019 and has now completed over 325,000 meters of drilling. The company has the world's largest, undeveloped high-grade silver resource. Learn more at⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠https://vizslasilvercorp.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Equinox has recently completed the business combination with Calibre Mining to create an Americas-focused diversified gold producer with a portfolio of mines in five countries, anchored by two high-profile, long-life Canadian gold mines, Greenstone and Valentine. Learn more about the business and its operations at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠equinoxgold.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Integra Resources is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho, and the Nevada North Project located in western Nevada. Learn more about the business and their high industry standards over at integraresources.com

​Attorney General Pam Bondi's recent announcement of releasing additional files related to Jeffrey Epstein has been met with skepticism, particularly following the underwhelming "Phase 1" release. The initial batch, which Bondi had hyped as containing "sick" revelations, primarily consisted of previously available flight logs and heavily redacted documents, offering little new information. This anticlimactic disclosure led to disappointment among the public and conservative influencers, who had anticipated more substantial revelations. Critics argue that the fanfare surrounding the release was disproportionate to its actual content, raising questions about the transparency and intentions behind these actions.In response to the backlash, Bondi has assured the public that more comprehensive documents will be forthcoming, blaming the initial shortcomings on the FBI's alleged withholding of thousands of pages. She has demanded that these documents be delivered to her office promptly, emphasizing a commitment to full transparency. However, given the previous overpromising and underdelivering, many remain skeptical about the authenticity and potential impact of the upcoming releases.to contact me:bobbycapucci@protonmail.comsoruce:Attorney General Pam Bondi insists more Jeffrey Epstein files are being released – despite disastrous ‘phase 1' | The IndependentBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-epstein-chronicles--5003294/support.

Synopsis: This episode is proudly sponsored by Quartzy. Roivant Sciences CEO Matt Gline returns to Biotech 2050 for a deeply reflective conversation with host Rahul Chaturvedi on what it really takes to build a biotech company that lasts. From Roivant's transformational $7B Pfizer-to-Roche deal to delivering registrational Phase 3 data in dermatomyositis—one of biotech's most difficult graveyard indications—Matt shares how disciplined execution, decentralization, and learning from failure shaped Roivant's trajectory. The discussion explores Roivant's unique “Vant” model, why multiple CEOs can outperform centralized command-and-control structures, and how thoughtful clinical trial design—down to steroid tapering and site execution—can make or break outcomes in rare disease development. Beyond science and strategy, Matt reflects candidly on his own evolution as CEO, the realities of leading a public biotech through volatile markets, and why authenticity, focus, and embracing hard lessons matter more than chasing hype. This episode is a masterclass in biotech leadership, clinical development, and long-term value creation. Biography: Matt Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy. Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.

Join me for an empowering conversation with Dr. Amy Killen, a board-certified emergency physician turned longevity expert, as we explore how women can thrive in their "Queen Phase"—the years following the loss of the protective "estrogen shield" . We dive deep into the nuances of Hormone Replacement Therapy, celebrating the recent FDA updates on estrogen and dispelling myths about testosterone for women . Dr. Killen breaks down the science of stem cells, explaining the difference between autologous (bone marrow/fat) and allogeneic sources, and shares vital red flags to watch for in regenerative clinics . We also discuss the critical link between mitochondrial health and sexual longevity, the potential of peptides like PT-141 and GHK-Cu, and why heavy lifting and sleep are non-negotiable for aging well . Guest Information: Dr. Amy Killen is the Co-Founder of Humanaut Health and the founder of the Human Optimization Project. You can find her at https://biorestoration.com/dt_team/person-01/ and on Instagram @DrAmyBKillen .

JCO PO author Dr. Shilpa Gupta at Cleveland Clinic Children's Hospital shares insights into her article, "Fibroblast Growth Factor Receptor 3 (FGFR3) Alteration Status and Outcomes on Immune Checkpoint Inhibitors (ICPI) in Patients with Metastatic Urothelial Carcinoma". Host Dr. Rafeh Naqash and Dr. Gupta discuss how FGFR3 combined with TMB emerged as a biomarker that may be predictive for response to ICPI in mUC. TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center. Today I am excited to be joined by Dr. Shilpa Gupta, Director of Genitourinary Medical Oncology at the Cancer Institute and co-leader of the GU Oncology Program at the Cleveland Clinic, and also lead author of the JCO PO article titled "Fibroblast Growth Factor Receptor 3 Alteration Status and Outcomes on Immune Checkpoint Inhibitors in Patients With Metastatic Urothelial Carcinoma." At the time of this recording, our guest's disclosures will be linked in the transcript. Shilpa, welcome again to the podcast. Thank you for joining us today. Dr. Shilpa Gupta: Thank you, Rafeh. Honor to be here with you again. Dr. Rafeh Naqash: It is nice to connect with you again after two years, approximately. I think we were in our infancy of our JCO PO podcast when we had you first time, and it has been an interesting journey since then. Dr. Shilpa Gupta: Absolutely. Dr. Rafeh Naqash: Well, excited to talk to you about this article that you published. Wanted to first understand what is the genomic landscape of urothelial cancer in general, and why should we be interested in FGFR3 alterations specifically? Dr. Shilpa Gupta: Bladder cancer or urothelial cancer is a very heterogeneous cancer. And while we find there is a lot of mutations can be there, you know, like BRCA1, 2, in HER2, in FGFR, we never really understood what is driving the cancer. Like a lot of old studies with targeted therapies did not really work. For example, we think VEGF can be upregulated, but VEGF inhibitors have not really shown definite promise so far. Now, FGFR3 receptor is the only therapeutic target so far that has an FDA approved therapy for treating metastatic urothelial cancer patients, and erdafitinib was approved in 2019 for patients whose tumors overexpressed FGFR3 mutations, alterations, or fusions. And in the landscape of bladder cancer, it is important because in patients with non-muscle invasive bladder cancer, about 70 to 80% patients can have this FGFR3. But as patients become metastatic, the alterations are seen in, you know, only about 10% of patients. So the clinical trials that got the erdafitinib approved actually used archival tumor from local cancer. So when in the real world, we don't see a lot of patients if we are trying to do metastatic lesion biopsies. And why it is important to know this is because that is the only targeted therapy available for our patients right now. Dr. Rafeh Naqash: Thank you for giving us that overview. Now, on the clinical side, there is obviously some interesting data for FGFR3 on the mutation side and the fusion side. In your clinical practice, do you tend to approach these patients differently when you have a mutation versus when you have a fusion? Dr. Shilpa Gupta: We can use the treatment regardless of that. Dr. Rafeh Naqash: I recently remember I had a patient with lung cancer, squamous lung cancer, who also had a synchronous bladder mass. And the first thought from multiple colleagues was that this is metastatic lung. And interestingly, the liquid biopsy ended up showing an FGFR3-TACC fusion, which we generally don't see in squamous lung cancers. And then eventually, I was able to convince our GU colleagues, urologists, to get a biopsy. They did a transurethral resection of this tumor, ended up being primary urothelial and synchronous lung, which again, going back to the FGFR3 story, I saw in your paper there is a mention of FGFR3-TACC fusions. Anything interesting that you find with these fusions as far as biology or tumor behavior is concerned? Dr. Shilpa Gupta: We found in our paper of all the patients that were sequenced that 20% had the pathognomonic FGFR3 alteration, and the most common were the S249C, and the FGFR3-TACC3 fusion was in 45 patients. And basically I will say that we didn't want to generate too much as to fusion or the differences in that. The key aspect of this paper was that historically there were these anecdotal reports saying that patients who have FGFR alterations or mutations, they may not respond well to checkpoint inhibitors because they have the luminal subtype. And these were backed by some preclinical data and small anecdotal reports. But since then, we have seen that, and that's why a lot of people would say that if somebody's tumor has FGFR3, don't give them immunotherapy, give them erdafitinib first, right? So then we had this Phase 3 trial called the THOR trial, which actually showed that giving erdafitinib before pembrolizumab was not better. That debunked that myth, and we are actually reiterating that because in our work we found that patients who had FGFR3 alterations or fusions, and if they also have TMB-high, they actually respond very well to single agent immunotherapy. And that is, I think, very important because it tells us that we are not really seeing that so-called potential of resistance to immunotherapy in these patients. So to answer your question, yeah, we did see those differences, but I wouldn't say that any one marker is more prominent. Dr. Rafeh Naqash: The analogy is kind of similar to what we see in lung cancer with these mutations called STK11/KEAP1, which are also present in some other tumors. And one of the questions that I don't think has been answered is when you have in lung cancer, if you extrapolate this, where doublet or single agent immunotherapy doesn't do as well in tumors that are STK11 mutated. But then if you have a high TMB, question is does that TMB supersede or trump the actual mutation? Could that be one reason why you see the TMB-high but FGFR3 altered tumors in your dataset responding or having better outcomes to immunotherapy where potentially there is just more neoantigens and that results in a more durable or perhaps better response to checkpoint therapy? Dr. Shilpa Gupta: It could be. But you know, the patients who have FGFR alterations are not that many, right? So we have already seen that just patients with TMB-high respond very well to immunotherapy. Our last podcast was actually on that, regardless of PD-L1 that was a better predictor of response to immunotherapy. So I think it's not clear if this is adding more chances of response or not, because either way they would respond. But what we didn't see, which was good, that if they had FGFR3, it's not really downplaying the fact that they have TMB-high and that patients are not responding to immunotherapy. So we saw that regardless, and that was very reassuring. Dr. Rafeh Naqash: So if tomorrow in your clinic you had an individual with an FGFR3 alteration but TMB-high, I guess one could be comfortable just going ahead with immunotherapy, which is what the THOR trial as you mentioned. Dr. Shilpa Gupta: Yes, absolutely. And you know, when you look at the toxicity profiles of pembrolizumab and erdafitinib, really patients really struggle with using the FGFR3 inhibitors. And of course, if they have to use it, we have to, and we reserve it for patients. But it's not an easy drug to tolerate. Currently the landscape is such that, you know, frontline therapy has now evolved with an ADC and immunotherapy combinations. So really if patients progress and have FGFR3 alterations, we are using erdafitinib. But let's say if there were a situation where a patient has had chemotherapy, no immunotherapy, and they have FGFR3 upregulation and TMB-high, yes, I would be comfortable with using only pembrolizumab. And that really ties well together what we saw in the THOR trial as well. Dr. Rafeh Naqash: Going to the clinical applications, you mentioned a little bit of this in the manuscript, is combination therapies. You alluded to it a second back. Everything tends to get combined with checkpoint therapy these days, as you've seen with the frontline urothelial, pembrolizumab with an ADC. What is the landscape like as far as some of these FGFR alterations are concerned? Is it reasonable to combine some of those drugs with immune checkpoint therapy? And what are some of the toxicity patterns that you've potentially seen in your experience? Dr. Shilpa Gupta: So there was indeed a trial called the NORSE trial. It was a randomized trial but not a comparative cohort, where they looked at FGFR altered patients. And when they combined erdafitinib plus cetrelimab, that did numerically the response rates were much higher than those who got just erdafitinib. So yeah, the combination is definitely doable. There is no overlapping toxicities. But unfortunately that combination has not really moved forward to a Phase 3 trial because it's so challenging to enroll patients with such kind of rare mutations on large trials, especially to do registration trials. And since then the frontline therapy has evolved to enfortumab vedotin and pembrolizumab. I know there is an early phase trial looking at a next generation FGFR inhibitor. There is a triplet combination looking in Phase 1 setting with a next generation FGFR inhibitor with EV-pembro. However, it's not a randomized trial. So you know, I worry about such kinds of combinations where we don't have a path for registration. And in the four patients that have been treated, four or five patients in the early phase as a part of basket trial, the toxicities were a lot, you know, when you combine the EV-pembro and an FGFR3 inhibitor, we see more and more toxicity. So the big question is do we really need the "kitchen sink" approach when we have a very good doublet, or unless the bar is so high with the doublet, like what are we trying to add at the expense of patient toxicity and quality of life is the big question in my mind. Dr. Rafeh Naqash: Going back to your manuscript specifically, there could be a composite biomarker. You point out like FGFR in addition to FGFR TMB ends up being predictive prognostic there. So that could potentially be used as an approach to stratify patients as far as treatment, whether it's a single agent versus combination. Maybe the TMB-low/FGFR3 mutated require a combination, but the TMB-high/FGFR mutated don't require a combination, right? Dr. Shilpa Gupta: No, that's a great point, yeah. Dr. Rafeh Naqash: But again, very interesting, intriguing concepts that you've alluded to and described in this manuscript. Now, a quick take on how things have changed in the bladder cancer space in the last two years. We did a podcast with you regarding some biomarkers as you mentioned two years back. So I really would like to spend the next minute to two to understand how have things changed in the bladder cancer space? What are some of the exciting things that were not there two years back that are in practice now? And how do you anticipate the next two years to be like? Maybe we'll have another podcast with you in another two years when the space will have changed even more. Dr. Shilpa Gupta: Certainly a lot has happened in the two years, you know. EV-pembro became the universal frontline standard, right? We have really moved away from cisplatin eligibility in metastatic setting because anybody would benefit from EV-pembro regardless of whether they are candidates for cisplatin or not, which historically was relevant. And just two days ago, we saw that EV-pembro has now been approved for localized bladder cancer for patients who are cisplatin ineligible or refusing. So, you know, this very effective regimen moving into earlier setting, we now have to really think of good treatment options in the metastatic setting, right? So I think that's where a lot of these novel combinations may come up. And what else we've seen is in a tumor agnostic trial called the DESTINY-PanTumor trial, patients who had HER2 3+ on immunohistochemistry, we saw the drug approval for T-DXd, and I think that has kind of reinvigorated the interest in HER2 in bladder cancer, because in the past targeting HER2 really didn't work. And we still don't know if HER2 is a driver or not. And at ESMO this year, we saw an excellent study coming out of China with DV which is targeting HER2, and toripalimab, which is a Chinese checkpoint inhibitor, showing pretty much similar results to what we saw with EV-pembro. Now, you know, not to do cross-trial comparisons, but that was really an amazing, amazing study. It was in the presidential session. And I think the big question is: does that really tell us that HER2-low patients will not benefit? Because that included 1+, 2+, 3+. So that part we really don't know, and I think we want to study from the EV-302 how the HER2 positive patients did with EV and pembro. So that's an additional option, at least in China, and hopefully if it gets approved here, there is a trial going on with DV and pembro. And lastly, we've seen a very promising biomarker, like ctDNA, for the first time in bladder cancer in the adjuvant setting guiding treatment with adjuvant atezolizumab. So patients who were ctDNA positive derived overall survival and recurrence-free survival benefit. So that could help us select moving forward with more studies. We can spare unnecessary checkpoint inhibitors in patients who are not going to benefit. So I think there is a lot happening in our field, and this will help do more studies because we already have the next generation FGFR inhibitors which don't have the toxicities that erdafitinib comes with. And combining those with these novel ADCs and checkpoint inhibitors, you know, using maybe TMB as a biomarker, because we really need to move away from PD-L1 in bladder cancer. It's shown no utility whatsoever, but TMB has. Dr. Rafeh Naqash: Well, thank you so much, Shilpa, for that tour de force of how things have changed in bladder cancer. There used to be a time when lung and melanoma used to lead this space in terms of the number of approvals, the biomarker development. It looks like bladder cancer is shifting the trend at this stage. So definitely exciting to see all the new changes that are coming up. I'd like to spend another minute and a half on your career. You've obviously been a leader and example for many people in the GU space and beyond. Could you, for the sake of our early career especially, the trainees and other listeners, describe how you focused on things that you're currently leading as a leader, and how you shaped your career trajectory over the last 10 years? Dr. Shilpa Gupta: That's a really important question, Rafeh, and you and I have had these discussions before, you know, being an IMG on visas like you, and being in different places. I think I try to make the most of it, you know, instead of focusing on the setbacks or the negative things. Like tried to grab the opportunities that came along. When I was at Moffitt, got to get involved with the Phase 1 trial of pembrolizumab in different tumor types. And just keeping my options open, you know, getting into the bladder cancer at that time when I wanted to really do only prostate, but it was a good idea for me to keep my options open and got all these opportunities that I made use of. I think an important thing is to, like you said, you know, have a focus. So I am trying to focus more on biomarkers that, you know, we know that 70% patients will respond to EV-pembro, right? But what about the remaining 30%? Like, so I'm really trying to understand what determines hyperprogressors with such effective regimens who we really struggle with in the clinic. They really don't do well with anything we give them after that. So we are doing some work with that and also trying to focus on PROs and kind of patient-reported outcomes. And a special interest that I've now developed and working on it is young-onset bladder cancer. You know, the colorectal cancer world has made a lot of progress and we are really far behind. And bladder cancer has historically been a disease of the elderly, which is not the case anymore. We are seeing patients in their 30s and 40s. So we launched this young-onset bladder cancer initiative at a Bladder Cancer Advocacy Network meeting and now looking at more deep dive and creating a working group around that. But yeah, you know, I would say that my philosophy has been to just take the best out of the situation I'm in, no matter where I am. And it has just helped shape my career where I am, despite everything. Dr. Rafeh Naqash: Well, thank you again. It is always a pleasure to learn from your experiences and things that you have helped lead. Appreciate all your insights, and thank you for publishing with JCO PO. Hopefully we will see more of your biomarker work being published and perhaps bring you for another podcast in a couple of years. Dr. Shilpa Gupta: Yeah, thank you, Rafeh, for the opportunity. And thanks to JCO PO for making these podcasts for our readers. So thanks a lot. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. DISCLOSURES Dr. Shilpa Gupta Stock and Other Ownership Interests: Company: BioNTech SE,  Nektar Consulting or Advisory Role: Company: Gilead Sciences, Pfizer, Merck, Foundation Medicine, Bristol-Myers Squibb/Medarex, Natera, Astellas Pharma, AstraZeneca, Novartis, Johnson & Johnson/Janssen Research Funding: Recipient: Your Institution Company: Bristol Myers Squibb Foundation, Merck, Roche/Genentech, EMD Serono, Exelixis, Novartis, Tyra Biosciences, Pfizer, Convergent Therapeutics, Acrivon Therapeutics, Flare Therapeutics, Amgen Travel, Accommodations, Expenses: Company: Pfizer, Astellas Pharma, Merck    

Later today, Minister for Children Norma Foley will launch the Action Plan on Childcare. Phase one of the plan includes increases to the income limit for the National Childcare Scheme, and a consultation aimed at reducing the cost of childcare to 200 euro per child per month in the lifetime of this Government.We speak to Elaine Dunne, Chair of the Federation of Early Childhood Providers ahead of the launch.

Minister for Children Norma Foley has launched the Action Plan on Childcare.Phase one of the plan includes increases to the income limit for the National Childcare Scheme, and a consultation aimed at reducing the cost of childcare to €200 per child per month in the lifetime of this Government.The Minister joins Ciara Doherty to discuss more…

In this episode of the ESCRS IME podcast series on the Digital Operating Room (DOR), Drs. Gerd Auffarth and Amir Hamid discuss how connected digital workflows are reshaping modern cataract surgery. Drawing on recent ESCRS survey data and their own clinical experience, they highlight how shifting from paper-based processes to integrated digital systems enhances efficiency, accuracy, surgeon comfort, and training. They also explore how tools such as heads-up displays, digital toric alignment, and recorded surgical videos contribute to more consistent outcomes and support ongoing surgical education. Don't miss this insightful episode and be sure to check out the other expert-led podcasts in the series! Independent medical education supported by Alcon (Gold) and Zeiss (Bronze).

In this episode of the IoT For All Podcast, Barry Libert, Chairman and CEO of HiveMQ, joins Ryan Chacon to discuss moving past the pilot phase in industrial IoT and AI. The conversation covers viewing businesses as data streaming entities, the importance of understanding one's data collection processes, aligning different tiers of employees to achieve success, the shift from connectivity to AI data platforms, the role of agentic workflows, and the type of leadership required to navigate the evolving landscape of data and AI.Barry Libert is the Chairman and CEO of HiveMQ. He has spent 40+ years as a board member, CEO, and serial entrepreneur. He founded and exited several businesses, advised more than 350 CEOs, and served on more than 35 boards in his career. Most recently, Barry transformed Anaconda into a unicorn, adding $100M in new ARR in 18 months based on a proprietary open- source/open-core commercialization GTM playbook he co-designed and implemented.Barry is focused on AI platforms with network effects and data moats. He has co-authored 6 books, 20+ ebooks, and 500+ articles in the WSJ, NYT, HBR, MIT, and Forbes. He has appeared on CNN, CNBC, Fox, NPR, and delivered 500+ speeches to 250,000+ people globally. Barry began his career with McKinsey & Company, was a managing director of John Hancock's $2B Real Estate Equity arm, and was a partner at Arthur Andersen. Barry is a graduate of Tufts University (BA) and Columbia University (MBA).HiveMQ is the Industrial AI Platform helping enterprises move from connected devices to intelligent operations. Built on the MQTT standard and a distributed edge-to-cloud architecture, HiveMQ connects and governs industrial data in real time, enabling organizations to act with intelligence. With proven reliability, scalability, and interoperability, HiveMQ provides the foundation industrial companies need to operationalize AI, powering the next generation of intelligent industry. Global leaders including Audi, BMW, Eli Lilly, Liberty Global, Mercedes-Benz, and Siemens trust HiveMQ to run their most mission-critical operations.Discover more about IoT and AI at https://www.iotforall.comFind IoT solutions: https://marketplace.iotforall.comMore about HiveMQ: https://www.hivemq.comConnect with Barry: https://www.linkedin.com/in/barrylibert/Subscribe on YouTube: https://bit.ly/2NlcEwmJoin Our Newsletter: https://newsletter.iotforall.comFollow Us on Social: https://linktr.ee/iot4all

This week's episode will be focusing on an update of a late-breaking abstract presented at ASH 2025 this past week: the Phase 3 BRUIN-CLL 313 trial looking at Pirtobrutinib vs Bendamustine/Rituximab in 1L Chronic Lymphocytic Leukemia (CLL).

PLD & PJ go over The Incredible Hulk which was the forgotten stepchild until Brave New World came out! Recorded 7-8 months ago and made public now as we unveil Phase 1 during my hiatus!

In this episode, Paula Swope shares her unfiltered, real-life experience with peptides—what actually happened when she started them, what helped, and what went sideways. This is not a “Peptides 101” episode. It's a candid walkthrough of her personal journey with Retatrutide, Sermorelin, and a Tesamorelin/Ipamorelin/BPC-157 blend, including the unexpected side effects, sleep disruptions, appetite changes, and the adjustments that ultimately made the protocol work for her. Paula breaks down how growth-hormone–stimulating peptides affected her body, why one blend left her feeling awful, how Sermorelin became a sleep game-changer, and what it's actually like to use Retatrutide—the experimental triple-agonist weight-loss drug from Eli Lilly that's making headlines after completing Phase 3 trials. She also discusses appetite suppression, slow and sustainable weight loss at midlife, muscle preservation, protein intake, constipation, and why sleep quality may be the most underrated factor in fat loss and emotional regulation. This episode is not medical advice. Paula is not a doctor and does not tell anyone what to take or how to dose. She shares her experience, emphasizes the importance of working with a licensed medical professional, and warns about the growing gray and black markets for unregulated peptides. If you're curious about peptides but want an honest, grounded perspective—without hype, fear-mongering, or social media nonsense—this episode offers clarity, nuance, and lived truth.

Vereinbare jetzt dein kostenloses Erstgespräch: www.andreasbaulig.de/termin In der heutigen Episode von Die Coaching-Revolution spricht Andreas Baulig darüber, warum die Wochen zwischen Weihnachten und Neujahr die vielleicht wichtigste strategische Phase deines ganzen Jahres sind und warum du genau jetzt dein Angebot, deine Positionierung und deine Strategie für 2026 neu ausrichten musst, statt wieder planlos ins nächste Quartal zu stolpern. Du erfährst, wie du unnötige Aufgaben und komplizierte Ideen radikal streichst, echte Klarheit über die wenigen Hebel gewinnst, die wirklich Umsatz und Marge bringen und wie du dir noch dieses Jahr im Erstgespräch den Input sicherst, um 2026 mit maximalem Fokus, einem starken Offer und einem klaren Wachstumsplan zu starten. Vereinbare jetzt dein kostenloses Erstgespräch: www.andreasbaulig.de/termin Andreas Baulig & Markus Baulig zeigen dir, wie du dich als einer DER Nr.1 Experten in deiner Branche positionieren kannst und hohe Preise ab 2.000 Euro (und mehr) für deine Angebote & Dienstleistungen abrufen kannst. Als Coaches, Berater und Experten automatisiert Kunden im Internet gewinnen. Wie du Online Marketing nutzen kannst, um deine Produkte und Dienstleistungen erfolgreich zu verkaufen.

Co-hosts Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Sciences Advisory Council, interview Fei Li Kuang, MD, PhD, an allergist and immunologist, at Northwestern Medicine, about receiving two APFED HOPE on the Horizon Grants. Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [:50] Co-host Ryan Piansky introduces this episode, brought to you thanks to the support of Education Partners GSK, Sanofi, Regeneron, and Takeda. Ryan introduces co-host Holly Knotowicz.   [1:14] Holly introduces today's topic, two APFED HOPE on the Horizon Pilot Grant Projects and today's guest, Fei Li Kuang, MD, PhD, an Assistant Professor in the Division of Allergy and Immunology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.   [1:42] Dr. Kuang is a physician-scientist who takes care of patients with eosinophilic disorders and also performs laboratory research on these disorders in her lab, often using patient samples. Holly thanks Dr. Kuang for joining us.   [2:05] As a child, Dr. Kuang always wanted to be a scientist. She is so grateful to live out her childhood dream, and it's because of the amazing people who have supported her, most importantly, her parents.   [2:29] In graduate school, Dr. Kuang studied B cells. When she went on to do an allergy fellowship, she thought she would study B cells and care for patients with B cell problems. Instead, she fell in love with allergy and eosinophilic disorders.   [2:50] Dr. Kuang is here, in part, because of the different mentors she has had, and in large part, because of the patients she has met along the way.   [3:20] Dr. Kuang had the opportunity to work with Amy Klion at the NIH in a clinical trial to treat patients with a drug that gets rid of eosinophils. She says it was a dream come true after her training.   [4:02] She says she learned so much about eosinophils, their unusual biology, and the mystery behind what they are here for. She got hooked.   [4:15] Dr. Kuang thinks the patients you meet in a clinical trial in a special place like NIH occupy a space in your heart that makes you want to keep working on the subject area.   [4:34] Patients in a clinical trial have given up a bunch of their time to travel to Bethesda, Maryland. For the trial Dr. Kuang participated in as a Fellow, it was a good year of their time to come out and do it.   [4:47] Dr. Kuang felt there were so many interesting questions, from an intellectual point of view, but there was also a real need from patients with chronic conditions. It was a beautiful opportunity to marry scientists with physicians in training.   [5:36] Dr. Kuang shares some knowledge about eosinophils. They are white blood cells that are in all of us. They have little pink packages or granules that "jumped out" in the light microscope almost 200 years ago, when we first identified them.   [6:00] Dr. Kuang says that animals, dating back to reptiles, and different species of dolphins, all have eosinophils. A veterinary scientist, Dr. Nicole Stacy of the University of Florida, has taken photos of eosinophils from all these different species.   [6:21] They've been around for a long time. What are they good for? What we know is that they are associated with disease conditions, such as asthma and others, including leukemia. Those were the classic first studies of eosinophils.   [6:42] Now, we have a different mindset about eosinophils from work by the late James Lee at Mayo Clinic, Arizona.   [6:58] Dr. Kuang credits Dr. Lee with suggesting that eosinophils not just cause us problems but also help treat parasitic infections, maintain tissue homeostasis, help wound healing, and tissue repair. That's a new area we are beginning to appreciate.   [7:41] Dr. Kuang says we need to be open-minded that in some circumstances, eosinophils may be helpful or innocent. Now we have tools to start to understand some of that. We need to collect information from patients being treated with medicines.   [8:10] Ryan tells of being diagnosed as a kid. Doctors explained to him that eosinophils fight parasites, but in some people, they get confused and attack the esophagus. That's EoE. That was easy to understand, but he knew that the researchers knew more.   [8:53] Ryan is grateful to the patient population around eosinophilic esophagitis, and is proud of APFED's support of patients and caregivers with HOPE Grants. APFED has the HOPE on the Horizon Research Program, entirely funded by community donations.   [9:13] To date, APFED has directed more than $2 million toward eosinophilic disease research initiatives through various grant programs. As a patient advocacy organization, APFED works with fantastic researchers who submit innovative research ideas.   [9:32] These research ideas go through an extensive and competitive peer-review process, supported by researchers and clinicians in the APFED community.   [9:42] Today, we're going to discuss two different projects supported by HOPE Pilot Grants with Dr. Kuang.   [10:00] Dr. Kuang thinks there are two ways these grant programs are important to patients. One is advancing research by nurturing seedling investigators. Dr. Kuang got her first grant when she was a Fellow. It was an incredible opportunity.   [10:25] These grant programs also nurture seedling ideas that don't have enough evidence yet to garner the larger NIH grants, and so forth. There are other sources for grants: pharmaceutical companies. The grant programs are for seeds.   [10:49] Patients need to know that there are new things that are given some chance of being tested out. Research takes some time, and the FDA process of getting a drug approved is long.   [11:04] For the newly diagnosed patient, it can feel overwhelming. It feels like there's a loss of control. Sometimes, participating in something like APFED, being part of a community, gives back a sense of control that is lost when you're handed a diagnosis.   [11:45] For patients who have had it for a long time, when they participate in research and become engaged in organizations like APFED, they know they may not directly benefit today, they may benefit later, but they hope future patients will benefit.   [12:21] That gives them a sense of control and hope that things will be better for the next generation. We all want that, especially in medicine, in something that we don't have a very deep understanding of.   [12:58] Dr. Kuang received two HOPE Pilot Grants, one in 2018 and one in 2022. The first grant was awarded when she was a Fellow at the NIH.   [13:05] That first grant explored some effects of eosinophilic depletion of pathogenic lymphocytes in hypereosinophilic syndrome and overlaps with EGIDs. Ryan asks for a broad overview of that research.   [13:25] When Dr. Kuang was a Fellow at the NIH, they were doing a Phase 2 clinical trial, looking at "blowing up" eosinophils in patients who have a lot of them, hypereosinophilic syndrome patients.   [13:39] They included patients who had eosinophilic GI disease, often beyond the esophagus. They may have esophageal involvement, but sometimes their stomach is impacted, sometimes their large bowel is impacted, with related symptoms.   [13:57] What Dr. Kuang and the team noticed in the trial was that just within that little group of patients, there were people who did well, and people who did much better than before, but would have recurrent symptoms, and with no eosinophils in their GI tissues.    [14:16] The researchers wanted to know what was causing these problems for the patient. If you take eosinophils away, what other factors will impact the immune system of the patient, semi-long-term?   [14:32] Their focus was on these groups of patients who had different responses. They looked at the white blood cells that had been previously described as being the responsible, "bad" T cells that lead to eosinophils in the gut.   [14:49] They found that the patients who had recurrent flares of the disease had more of the bad T cells, and the patients who responded well and never complained again about symptoms did not.   [15:03] That allowed researchers to identify that there were subsets of patients with the disease that they were calling the same thing.   [15:18] Dr. Kuang says that work also led them to find that those cells were being reported in patients who had food allergies for which they needed an epinephrine auto-injector.   [15:27] The researchers were curious whether that was just a food allergy issue, or only applied if you had food allergies and eosinophilic GI disease. That HOPE project allowed them to do a pilot study to look at food allergy patients, too. They did, and published it.   [15:45] They published that in patients who have a food allergy and have these T cells, the insides of those cells make different messages for the immune system than the ones that the researchers had previously described.   [16:01] In looking for why there were differences in those responses, they accidentally found that there were differences inside these cells in a completely different disease, which also had these T cells.   [16:21] Dr. Kuang says that the finding was kind of a surprise. If they had found anything in the eosinophilic GI disease patients, that would have been good. They also looked at the epithelial cells and the structure of the GI lining.   [16:42] Even though there were no eosinophils in the GI lining in the patients who had been treated with a biologic that depleted eosinophils, their GI lining still looked like the GI lining of patients who had eosinophilic GI disease.   [16:55] Dr. Kuang asked what was creating those spots. Our gut lining sheds, so there should have been an opportunity for the GI lining to turn over and look new. Something was there, making signals to create these spots. They did a different publication on that.   [17:21] The data from the HOPE Pilot study allowed Dr. Kuang to apply for larger grants. It allowed her to propose to the company that made this drug, when they did the Phase 3 trial, to insert into that special study the study on eosinophilic GI disease.   [17:48] Do patients with eosinophilic GI disease do better or worse on this drug, and how do the T cells look in that trial? That HOPE Grant gave Dr. Kuang the data to ask the drug company to give her money to study it in an international cohort of patients.   [18:17] There were only 20 patients in that first NIH trial, who gave a year of their life, coming to NIH all the time. They continued to be in the study until the drug was approved for asthma.   [18:28] Dr. Kuang says the main reason the company did the Phase 3 trial, which is expensive, and the market share is not huge because it's a rare disease, is that two of the patients went to bat for this disease population.   [18:47] The two patients went and showed the business people what they looked like before, what the drug had done for them, and how their lives had changed. It wasn't the doctors or the great paper from the trial, but the patients who convinced the company.   [19:01] Dr. Kuang says she was so floored by that and moved by what they did for the community. She is grateful.   [19:24] Since the Phase 3 trial, Dr. Kuang and the other researchers realized they had not fully studied the eosinophils. They had studied them in part. They found differences in response. This inspired the second APFED HOPE Pilot Grant.   [21:19] In 2022, Dr. Kuang received a two-year APFED HOPE Pilot Grant to examine how blood eosinophils in Eosinophilic Gastrointestinal Diseases differ from those of other eosinophilic diseases and how T cells in EGIDs differ from those in food allergies.   [21:49] Dr. Kuang says normally, the biggest place of residence for eosinophils is the GI tract. That's where they are normally seen in people who do not have eosinophilic disorders.   [21:59] People who have eosinophilic disorders that attack other parts of the body, asthma, and rarely, the heart. Dr. Kuang was curious to know why one person and not the other?   [22:15] Patients who have eosinophilic GI disease often ask, How do you know this high level in the blood is not going to attack my heart or my lungs in the future? Dr. Kuang does not know.   [22:29] Dr. Kuang says, looking at the cohort at the NIH, that for many patients who have both GI organ involvement and some other space, when they first went to see a provider, their first complaint was a GI condition.   [22:54] If the doctor had only diagnosed a GI condition, nothing else, that would have been wrong. Those patients may not have been monitored as well. A third of the patients originally presented like that.   [23:11] What that meant was that we should be paying attention to patients who have GI disease who have lots of eosinophils in their blood. Moving forward, if there are new complaints, we need to investigate. We can't forget they have that.   [23:27] Dr. Kuang asks, Wouldn't it be great if we had a better tool than needing to wait? Wouldn't it be great if we had a biomarker that said the eosinophils have switched their target location and are going somewhere else?   [23:41] One way to do that is to take different groups of eosinophils and look for differences between those that never target the GI tract and those that do. In patients who have EoE, the eosinophils only target or cause problems in the esophagus.   [23:58] Are their eosinophils any different than those of a healthy person, with none of these conditions? That was the goal of that study.   [24:10] T cells are another type of white blood cell. They contain a memory of foreign things they have encountered, which allows them to glom onto flu, COVID, peanuts, pollen, that kind of thing. They remember.   [24:32] Dr. Kuang says they learned that T cells, at least in the mouse model, are required in the development of eosinophilic esophagitis. The mice in the old study, where mice were forced to develop EoE, did not get EoE if you removed their T cells.   [24:50] In the first APFED HOPE grant study, Dr. Kuang found T cells in the blood and tissue of both EGIDs and food allergy patients, but the insides of the T cells were different. The food allergy patients were children recruited by a pediatric allergist.   [25:19] In the second APFED HOPE grant study, at Northwestern, Dr. Kuang recruited her adult food allergy patients. That was a way to validate what they found in the first study and move further to better characterize those T cells in the two different diseases.   [25:47] Dr. Kuang says we're at a point where we've recruited a lot of people. She says it's amazing what people are willing to do. It's very humbling.   [26:06] Dr. Kuang's team in the lab is really great, too. To accommodate patients, they would see them after work, if that's what they had to do to isolate eosinophils. So they did that, and now they are in the process of analyzing that data. It's really exciting.   [26:28] What's exciting is that they are seeing results that show that eosinophilic GI disease patients have circulating eosinophils that are different from the eosinophils of people who don't have GI involvement, and from people who have EoE.   [26:46] The EoE patients have eosinophils different from those of healthy donors. Dr. Kuang says there's a lot of promise for perhaps unique signatures that could help define these conditions; maybe someday without biopsying, but that's a long time away.   [27:16] Dr. Kuang says they will focus on some candidate targets and try to recreate some of that in a dish with eosinophils from healthy people.   [27:26] What are the signals that lead eosinophils to do this, and can we translate that back to available drugs that target certain cytokines or other pathways, and maybe give some insight to develop drugs that target other pathways for these diseases?   [28:17] Ryan thinks it's exciting that this research is narrowing in on not only the different symptoms, but also how the eosinophils are acting differently in these populations.    [28:44] Dr. Kuang is super excited about this research. You could imagine that all eosinophils are the same, but you don't know until you look. When they looked, using the newest technology, they found there were differences.   [29:33] Dr. Kuang says it is thought that T cells respond to triggers. We don't think eosinophils have a memory for antigens. T cells do. That's one of their definitions. When T cells react to a trigger, they give out messages through cytokines or by delivery.   [30:20] Those are the messages that recruit eosinophils and other cells to come and stir up some trouble.   [30:28] In the mouse model, where you don't have the T cells, and you don't get eosinophilic esophagitis in the particular way they made it happen in a mouse, that middle messenger is gone, so the eosinophils don't know where to go.   [30:44] With drugs that take out eosinophils, you think that you've gotten rid of the cell that creates all the problems. It shouldn't matter what the message says because there's no cell there to cause the damage.   [30:58] What Dr. Kuang learned is that, at least in certain eosinophilic GI diseases, that's not true. You erase the eosinophils from the picture, but that message is still coming.   [31:10] Who's carrying out the orders? Or is that message maintaining the wall of epithelial cells in a certain way that we didn't appreciate because the eosinophils were also there?   [31:24] It's important to study both, because one is the messenger and the other is one of the actors. Whether all of the actions taken by eosinophils are bad, or maybe some of them were meant to be good, we have yet to learn.   [31:40] At the moment, we're using it as a marker for disease activity, and that may change in the future, as we learn more about the roles of these cells in the process.   [31:50] We have drugs now that target eosinophils and drugs that target T cells. Dr. Kuang thinks it's important to study both and to study the impact of these drugs on these cells.   [32:02] You could theoretically use these drugs to understand whether, if someone responds to it, what happens to these cells, and if someone doesn't respond to it, what happens to these cells, and how this disease manifests in this flavor of patients.   [32:54] Dr. Kuang says, Often in science, we take a model. We think this works this way. Then, if this works this way, we expect that if we remove this, these things should happen. We did that with the first clinical trial, with NIH patients.   [33:10] It didn't quite happen the way we thought, so we had to go looking for explanations. These were unusual setbacks. Sometimes you have unusual findings, like the food allergy part.   [33:24] When Dr. Kuang went to Northwestern, she saw different cohorts of patients than she saw at NIH. She saw people who were seen every day, which is a different spectrum than those who are selected to be enrolled in a study protocol at the NIH.   [33:42] That broadened her viewpoint. It's maybe not all food-triggered. They were seeing adults who'd never had food allergies or asthma their whole life, and they had eosinophilic esophagitis suddenly as a 50-year-old. There's a significant group of them.   [34:10] What Dr. Kuang learned and tries to be open-minded about is that where you train, what sorts of patients you see, really shape your viewpoint and thinking about the disease process and the management process.   [34:24] Dr. Kuang says she was so lucky to have experienced that at a quaternary care referral center like the NIH and at an academic center like Northwestern, where there are fantastic gastroenterologists who see so many of these patients.   [34:56] Dr. Kuang and an Allergy Fellow knew they were going to get a wonderful data set from the NIH patients they had recruited, so they thought they had better look deeply at what had been learned before with older technology, with mice and people.   [35:13] They decided to gather previous research, and that ultimately got published as an article. From that research, they learned that people did things in many different ways because there was no standard. They didn't know what the standard should be.   [35:28] Different things you do to try to get eosinophils out of tissue impact how they look, in terms of transcript, gene expression, and what messages they make to define themselves as an eosinophil.   [35:43] They also learned that because eosinophils are hard to work with, they die easily, and you can't freeze them and work on them the next day; you can introduce issues in there that have to be accounted for.   [35:59] They learned that as an eosinophil research community, they ought to come up with some standards so that they can compare future studies with each other. Dr. Kuang says it was impossible to compare the old studies that used different premises.   [36:50] Dr. Kuang says we need to be proactive in creating the datasets in a standard way so that we can compare and have a more fruitful and diverse community of data. It's hard to use the old data.   [37:57] Dr. Kuang says they get fresh blood from patients, and because eosinophils are finicky, they need to be analyzed within four hours, or preserved in a way to save whatever fragile molecules are to be studied.   [38:19] If you let it sit, it starts dying, so you won't have as many of them, and they start changing because they're not in the body. Dr. Kuang experimented with putting a tube of blood on the bench and checking it with the same test every two hours. It changes.   [38:38] Four hours is a standard to prevent the eosinophils from dying. Patients need treatment. If a patient is hospitalized and needs treatment, Dr. Kuang's team needs to be there to get a sample before treatment is started.   [39:03] The treatment impacts it, changing the situation. Much of the treatment, initially, is steroids. When you give lots of steroids, the eosinophils go away. It's no good to draw their blood then.   [39:27] Dr. Kuang also gets a urine sample. The granules of the eosinophils can get into the urine. As they study people with active disease, they want to capture granule proteins in the urine as a less invasive way to monitor activity in different disease states.   [40:04] The patient just needs to give Dr. Kuang either arm and a urine sample.   [41:04] Dr. Kuang explains, you can count your eosinophils after four hours, but to study them, they have different flags of different colors and shapes. Those colors and shapes may mean that it's an activated eosinophil, or they may have other meanings.   [41:41] Dr. Kuang focused on markers that look at whether it's going to spill its granules and some traditional markers of activation.     [41:50] Everyone chooses a different marker of activation. So they decided to look at as many as they could. One marker is not sufficient. They seem to be different in different conditions. The markers are on the surface; you need to analyze them right away.   [42:20] Then, Dr. Kuang breaks open the eosinophils and grabs the messenger RNA. They preserve it to do sequencing to read out the orders to see what this eosinophil is telling itself to make. RNA chops up messages.   [43:00] When you open an eosinophil, a protein you find is RNA, which chops up messages, destroying parts of the cell. You want to save the message. There's a brief time to analyze the eosinophil. Dr. Kuang works to preserve and read the message.   [44:04] Dr. Kuang hopes someday to run a tube of blood, look at the flags on the eosinophils, and say, "I think your eosinophilic GI disease is active," or "You have a kind of eosinophilic GI disease we need to monitor more frequently for organ damage."   [44:38] If another patient doesn't have those flags, Dr. Kuang could say, "I think the chances that you're going to have involvement elsewhere are low." That can give reassurance to folks who are worried.   [45:15] Dr. Kuang hopes that someday we can understand better why some people have food allergies vs. eosinophilic GI disease. They both have T cells, but the T cells have different packages inside with messages to deliver.   [45:34] Every day, Dr. Kuang has to tell patients she doesn't have that answer. Someday, she hopes she can tell a patient she does have that answer.   [46:35] Dr. Kuang tells about an NIH grant she's excited about and the patients she recruits after therapy, or elimination diets, to examine eosinophils and T cells, to see the impacts their treatments or diets have had on eosinophilic GI disease.   [47:18] Dr. Kuang believes there will be predictors of who will respond to an elimination diet and who will respond to steroid therapy. She hopes one day to have that, rather than going through rounds of six to eight weeks followed by a scope.   [47:34] If you have an elimination diet for six to eight weeks, every time you add back a food, you have to do a scope. Dr. Kuang says it would be great if you could be more precise ahead of time for therapy.   [47:48] Dr. Kuang says these wonderful drugs selectively take out parts of the pathway in the immune system. They provide real-life opportunities to ask, why is this important in human biology and the human immune system?   [48:15] Dr. Kuang finds the knowledge itself fascinating and useful. She hopes it informs how we choose future drugs or therapeutic avenues to get the best we can out of what we've learned, so we have more targeted ways of treating specific diseases.   [48:48] Ryan is grateful for all the research happening for the eosinophilic disease community and all the patients participating in the research. He asks Dr. Kuang how a patient can participate in research.   [49:12] There are lots of ways to be involved in research. Dr. Kuang says her patients come away from participating in research feeling good about having done it.   [49:22] Answer a survey, if that's what you have bandwidth for. Where therapies are changing, being a part of a community is good for the community, for the future, but it's good for you, too. It's healing in ways that are not steroids or biologics.   [49:58] Being part of a community is healing in ways we all need when we feel alone and bewildered. You're not alone.   [50:12] There are many ways to participate: APFED, CEGIR, individual institutions, and clinical trials. They all have different amounts of involvement. It's worthwhile to participate, not only for future patients but for yourself. They're fantastic!   [50:56] Dr. Kuang talks about the privilege as a physician of working with APFED and other organizations to do this work.   [51:09] Holly thanks Dr. Kuang for sharing all of this research and exciting information.   [51:25] Dr. Kuang is excited about what her group is doing and is hopeful. Besides showing up for this disease, we have to show up for research, in general, in this country. It's a dark time for NIH research funding.   [51:55] Dr. Kuang asks the young listeners who are thinking of choosing a field to see the potential and get into it, study this, and believe that there's going to be a future with a more nurturing research environment.   [52:36] Dr. Kuang would hate to lose generations of scientists. She says that once she was a little girl who was trying to be a scientist. Her parents had no connections with scientists or doctors, but she was able to get into research, and she thinks you can, too.   [53:48] As a graduate student, Ryan has always been interested in trying to improve things, and he sees hope on the horizon. He's very grateful to the APFED community for supporting these research HOPE Pilot Grants.   [54:17] Ryan is very grateful to Dr. Kuang for joining us today.   [54:22] For our listeners who want to learn more about eosinophilic disorders, we encourage you to visit apfed.org and check out the links in the show notes.   [54:28] If you're looking to find a specialist who treats eosinophilic disorders, we encourage you to use APFED's Specialist Finder at apfed.org/specialist.   [54:37] If you'd like to connect with others impacted by eosinophilic diseases, please join APFED's online community on the Inspire Network at apfed.org/connections.   [54:57] Dr. Kuang thanks Ryan and Holly and says she enjoyed the conversation. Holly also thanks APFED's Education Partners GSK, Sanofi, Regeneron, and Takeda for supporting this episode.   Mentioned in This Episode: Fei Li Kuang, MD, PhD, Allergist and Immunologist, Northwestern Medicine   Grants and publications discussed: Apfed.org/blog/apfed-announces-2018-hope-apfed-hope-pilot-grant-recipient/ Apfed.org/blog/fei-li-kuang-hope-pilot-grant-award/  Pubmed.ncbi.nlm.nih.gov/39213186/ Pubmed.ncbi.nlm.nih.gov/37487654/   APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast apfed.org/specialist apfed.org/connections apfed.org/research/clinical-trials   Education Partners: This episode of APFED's podcast is brought to you thanks to the support of GSK, Sanofi, Regeneron, and Takeda.   Tweetables:   "I think the patients that you meet in a clinical trial, especially in a special place like NIH, occupy a space in your heart — I don't mean to be all too emotional about this — that makes you want to keep working on the subject area." — Fei Li Kuang, MD, PhD   "When I was a Fellow at the NIH, we were doing a Phase 2 clinical trial, looking at, for want of a better word, "blowing up" eosinophils in patients who have a lot of them, hypereosinophilic syndrome patients." — Fei Li Kuang, MD, PhD   "We're at a point where we've recruited a lot of people. I've had patients drive from the northern part of Illinois … come down and give me blood. It's amazing what people want to do and are willing to do. It's very humbling, actually." — Fei Li Kuang, MD, PhD   "You erase the eosinophils from the picture, but that message is still coming. Who's carrying out the orders? Or is that message maintaining the wall of epithelial cells in a certain way that we didn't appreciate because the eosinophils were also there?" — Fei Li Kuang, MD, PhD   "We need to be proactive in creating the datasets in a standard way so that we can compare and have a more fruitful and diverse community of data." — Fei Li Kuang, MD, PhD   "I think it's worthwhile to participate [in a clinical trial], not only for the future people but for yourself." — Fei Li Kuang, MD, PhD   Guest Bio: Fei Li Kuang, MD, PhD, is currently an Assistant Professor in the Division of Allergy and Immunology at Northwestern University Feinberg School of Medicine in Chicago, IL. She is a graduate of the Albert Einstein College of Medicine Medical Scientist Training Program with both a PhD in Cell Biology/Immunology and an MD.  She completed her Internal Medicine Residency at Columbia University, New York Presbyterian Hospital in New York City, she did her Fellowship in Allergy and Immunology at the National Institute of Allergy and Infectious Disease (NIAID) in Bethesda, Maryland. She is a physician-scientist who takes care of patients with eosinophilic disorders and also performs laboratory research on these disorders in her lab, often using patient samples.

In Part 1 of this two-part Christmas special, Bryan sits down with Captain Anthony Element-Malouin, a CC-130J Hercules pilot with 436 Transport Squadron, to explore his path from early inspiration to operational flying in the RCAF. The conversation dives into the realities of RCAF pilot training, including Phase 1 in Portage, the challenges of Phase 2 on the CT-156 Harvard II, air sickness, spin course, test anxiety, and the perseverance required to push through setbacks. Tony also reflects on earning his wings, transitioning to the Hercules, deploying shortly after OTU on Op Reassurance, and preparing for Operation Christmas Drop during the Christmas season this year!

If YOU'RE ready to make real, sustainable change in your life, jump on a free call with us - https://physiquedevelopment.typeform.com/to/ToP9TYLEOver the past few episodes, Sue and Alex have unpacked the truth about bulking—why a massive surplus isn't necessary and what actually drives muscle growth. In today's episode, they dive into how long your muscle-building phase should be. So if you want efficient results and want to feel good while getting there, this episode is for you.They break down what a real, effective, feel-good build phase looks like, and what needs to be addressed before the build even begins. They also explain the optimal length for a muscle-building phase and why staying in hypertrophy for months on end often leads to stalled progress, not better results. Muscle growth requires complementary phases and intentional planning, not just grinding harder in the gym.Because you don't need more effort, you need a better system—one that supports your body, respects your life, and delivers lasting results.Have questions or comments for the podcast? Drop them here - https://forms.gle/AEu5vMKNLDfmc24M7Check out our FREE 4-Week Glute Program - https://go.physiquedevelopment.com/freegluteprogram701788And keep the gains rolling with 12 MORE weeks of glute growth (use code POD at checkout for $25 off!) - https://train.physiquedevelopment.com/workout-plans/963551As always, it is our goal not only to supply you, the listener, with valuable insights on the topics or questions but also to plant some seeds for further research and thought. Be sure to like and subscribe and leave us a review wherever you're listening if you loved this episode!Timestamps:(0:00) Today's topic(1:20) The recovery phase (where a successful muscle-building phase *actually* begins)(5:18) What you can expect during a recovery phase(5:55) Training during the recovery phase(6:30) How long a muscle-building phase should last(7:19) Setting your calories and macros for your build(8:37) Adjustments to training to optimize muscle gain(15:25) How much weight you should gain during a build (and how quickly)(17:11) The most important markers to keep an eye on(22:18) The best way to ensure a successful building phaseFollow us on Instagram:Coach Alex - https://www.instagram.com/alexbush__Coach Sue - https://www.instagram.com/suegainzPhysique Development - https://www.instagram.com/physiquedevelopment_Physique Development Podcast - https://www.instagram.com/physiquedevelopmentpodcast----Produced by: David Margittai | In Post MediaWebsite: https://www.inpostmedia.comEmail: david@inpostmedia.com© 2025, Physique Development LLC. All rights reserved.

In this episode of the Female Health Solution Podcast, I break down one of the biggest frustrations women face: Your labs come back "normal," yet you still feel exhausted, inflamed, moody, or nothing like yourself, and no one can explain why. Here's what we cover: Why basic blood work misses the real problem Regular labs look for disease, not dysfunction. A standard CBC or hormone panel can't show how your hormones are produced, processed, or eliminated. Blood tests catch crises, not the early warning signs of perimenopause, adrenal burnout, or estrogen dominance. What DUTCH urine hormone testing reveals that blood work can't All three estrogens: E1, E2, and E3 Phase 1 and Phase 2 estrogen detox (your liver pathways) Methylation which is a major cause of PMS, migraines, brain fog, and mood swings Cortisol rhythm throughout the day Nutrient deficiencies and gut-related patterns This level of detail finally explains why you feel off and what to do about it. Real client stories Sara's story: Blood labs said "you're fine." Her DUTCH test showed exactly why she had migraines, poor sleep, and terrible PMS. Within months on a targeted plan, PMS dropped by 50 percent and her menstrual migraines disappeared. At her follow-up, her clinic literally told her, "We don't know how to read this." Jenna's story: A mom of five determined not to be a "half version" of herself. She researched every option and realized she would have to piece together three times the number of tests to get what DUTCH shows in one report. Once she saw her results, she finally had a roadmap instead of guessing. Why your hormone issues are never just one thing Your genetics, stress load, pregnancies, environmental toxins, sleep, and nutrient status all intersect. DUTCH shows which pieces are breaking down: production, processing, or elimination, so you stop guessing and start targeting the right areas. Why DUTCH is the roadmap your health has been missing This test shows: Where the "holes in your boat" actually are Which systems need support What is driving your symptoms And exactly what to do next Instead of random supplements, you get clarity. Ready for real answers? If you're tired of hearing "your labs are normal" while your body tells a different story, it's time to go deeper. You can: Order a DUTCH test through us Get a personalized review and plan from my team Finally understand your hormone story and what your body has been trying to tell you Order your hormone test: https://drbethwestie.com/dutch-hormone-testing/

The Big 12 discussing private capital deal with RedBird Capital Partners and Weatherford Capital; Phase 3 of World Cup tickets sees five million requests; the NWSL approves high impact player roster mechanism and Michigan expands athletic department probe. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Phase VIII: Celebrate and Integrate the New State is key to the full adoption of your solution. Its first Activity focuses on acknowledging the work done to implement the Desire State solution so that people recognize that their reality is now different and they can feel a part of having successfully achieved it in the organization. The second Activity is a key one to enable full adoption. Its first task is designed to support individuals and intact work teams to openly and safely discuss what is working, what still needs attention, and what might now need to be improved for optimal performance. Its second task focuses on the whole system engaged or impacted by the New State solution now that it has been implemented. All stakeholders gather to describe their part in the New State, what they need to fulfill their purpose and what they offer to others once the do. This enables everyone to see the full picture of how the New State needs to operate to fully achieve its results.Hosted on Ausha. See ausha.co/privacy-policy for more information.

The Phase No One Talks About: Slow Rebuild, Nervous System Repair, and Why I Went QuietHey friends, it's Lydia. It's been a little quiet here on the podcast — not because I didn't want to show up, but because my own system needed a pause. My body was asking for space to recalibrate, to integrate, to just be. And as I slowed down, I realized something: the pause itself was a signal — not just for me, but for the people I work with every day.We rarely talk about the phase that comes after crisis, after the acute danger has passed. You're no longer in emergency mode, you feel some relief… but something still feels off. Energy dips, digestion wobbles, micro-flares appear, and your nervous system feels “functional but not free.” This is the Slow Rebuild Phase — the longest, quietest, and most misunderstood stage of healing. And yet, it's where the deepest repair happens.In this episode, I give you a window into what's happening biologically, metabolically, and neurologically during this in-between stage. I explain why your metabolism might feel cautious, why your gut microbes are slow to wake up, and why your nervous system is testing safety every single day. I describe the micro-flares — the subtle digestive shifts, energy crashes, sinus irritations, emotional spikes, or tension patterns — that are actually proof your system is learning to trust itself again.I also talk about why people get stuck here: the urge to push harder, the pressure to see immediate progress, and the challenge of trusting a body that has spent years in survival mode. Most importantly, I share why slowness isn't stagnation — it's strategy. Rebuilding capacity, restoring stability, and cultivating safety in your body takes time, pacing, and gentle, intentional steps.Throughout the episode, I weave in my own recent experience of stepping back from the podcast, reorganizing my business structures, and intentionally moving slowly. It's living proof of what it looks like to honor this phase, to prioritize stability over speed, and to rebuild from a place of nervous system alignment rather than urgency.If you're listening to this and realizing you're in that in-between phase — not in crisis anymore, but not fully restored — this is exactly the phase I support clients through.I work one-on-one using minerals, microbiome data, and nervous system mapping to help your body stabilize, repair, and move forward at the pace it can actually handle.If you want to explore working together, you can find the details HERE. You don't need to do more.You need the right support at the right time.For more on this, check out my blog post, Rebuilding Capacity: The Missing Piece in Chronic Health Recovery, where I go deeper into the biology and practical guidance for navigating this phase. Mineral Foundations Course HERE Minerals and microbes package HERE Rewilded Wellness program HERE Join my newsletter HERE If you are interested in becoming a client and have questions, reach out by emailing me: connect@lydiajoy.me Find me on Instagram : @ Lydiajoy.me OR @ holisticmineralbalancing

Syrians are celebrating one year of freedom from the Assad regime, but there are many wounds still to be healed, and the work of transitional justice must now take place. It's a process that links Syria to the US, South Africa and many other countries in between. Ruti Teitel, professor of law at New York Law School and author of "Presidential Visions of Transitional Justice" and Aria Florant, co-founder and CEO of Liberation Ventures, an organization advocating for slavery reparations in the US, join the show.   Also on today's show: Guardian columnist Jonathan Freedland; law school professor Kate Shaw    Learn more about your ad choices. Visit podcastchoices.com/adchoices

Join for a live in person event in Newark New Jersey on February 27 through March 1st https://www.brianscottlive.com/february-2026 Join The Reality Revolution Tribe